Biomarkers of t cell reactivity

By determining specific biomarkers, the method enhances the assessment of hematological diseases, improving immune fitness evaluation and therapy guidance.

WO2026234275A1PCT designated stage Publication Date: 2026-11-12DEUTES KREBSFORSCHUNGSZENT STIFTUNG DES OFFENTLICHEN RECHTS +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063501
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

There is a need for improved methods to assess hematological diseases, particularly evaluating immune fitness in hematological neoplasia, as current methods are inadequate.

Method used

A method involving the determination of at least five biomarkers selected from a list of 30, including GNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, and others, to assess hematological diseases, which can be performed in vitro or ex vivo and may include computer-implementation, with results aiding in immune status evaluation and therapy recommendations.

Benefits of technology

The method provides a more accurate assessment of immune fitness and hematological disease, enabling better treatment decisions, particularly in determining immune responsiveness and predicting therapy outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000043_0001
    Figure IMGF000043_0001
  • Figure IMGF000043_0002
    Figure IMGF000043_0002
  • Figure IMGF000043_0003
    Figure IMGF000043_0003
Patent Text Reader

Abstract

The present invention relates to a method for assessing a hematological disease in a sample of a subject, said method comprising (a) determining in said sample at least five biomarkers selected from the list consisting of GNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, CCL5, HOPX, KLRD1, EFHD2, CD8A, CTSW, CST7, ITGB1, BHLHE40, LYAR, S100A4, GZMA, MXRA7, KLRK1, SH3BGRL3, ITGA4, FCRL6, TGFB1, CCL4, ZEB2, AOAH, AHNAK, S100A10, LGALS1, PRF1, ITGB2, CD52, TPST2, PRSS23, ANXA1, CYBA, C12orf75, LAIR2, MATK, S100A6, TNFAIP3, CLIC1, KLF6, C1orf21, SYNE2, HLA-DPB1, HLA- DPA1, DSTN, CD99, TAGLN2, PLEK, LINC02446, RPS26, RGCC, NFKBIA, FOS, PPP2R5C, CRIP1, AKAP13, ZFP36, and FLNA; and (B) thereby assessing said hematological disease. The present invention further relates to methods, systems, kits and databases related thereto.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Deutsches Krebsforschungszentrum 1 DK17411PC Stiftung des öffentlichen Rechts et al.

[0002] Biomarkers of T cell reactivity

[0003] Technical Field

[0004] The present invention relates to a method for assessing a hematological disease in a sample of a subject, said method comprising (a) determining in said sample at least five biomarkers selected from the list consisting of GNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, CCL5, HOPX, KLRD1, EFHD2, CD8A, CTSW, CST7, ITGB1, BHLHE40, LYAR, S100A4, GZMA, MXRA7, KLRK1, SH3BGRL3, ITGA4, FCRL6, TGFB1, CCL4, ZEB2, AOAH, AHNAK, S100A10, LGALS1, PRF1, ITGB2, CD52, TPST2, PRSS23, ANXA1, CYBA, C12orf75, LAIR2, MATK, S100A6, TNFAIP3, CLIC1, KLF6, C1orf21, SYNE2, HLA-DPB1, HLA-DPA1, DSTN, CD99, TAGLN2, PLEK, LINC02446, RPS26, RGCC, NFKBIA, FOS, PPP2R5C, CRIP1, AKAP13, ZFP36, and FLNA; and (B) thereby assessing said hematological disease. The present invention further relates to methods, systems, kits and databases related thereto.

[0005] Background art

[0006] The field of immune therapies has expanded vastly over recent years. Clinically, determining immune fitness of a patient and monitoring therapy effect currently mainly use histopathological and genomic characterization of tumor samples. In particular, PD-L1 expression, tumor mutation burden, microsatellite instability, and POLE mutations, in particular in the context of immune checkpoint blockade (ICB) have been used (Wang et al., 2022; Catalano et al., 2023). Also, Al approaches to establish biomarker combinations have been proposed (Ligero et al., 2025).

[0007] Moreover, single cell sequencing was used to identify tumor reactive T cells on the basis of transcriptome profiles, e.g. for NSCLC (Caushi et al., 2021) and in metastasizing solid tumors (Lowery et al., 2022).

[0008] Problem to be solved

[0009] There is, nonetheless, a need in the art for improved means and methods for assessing hematological disease, in particular evaluating immune fitness in hematological neoplasia. This problem is solved by the means and methods disclosed herein with the features of theDeutsches Krebsforschungszentrum 2 DK17411PC Stiftung des öffentlichen Rechts et al.

[0010] independent claims. Advantageous embodiments which might be realized in an isolated fashion or in any arbitrary combinations are listed in the dependent claims.

[0011] Description of the invention

[0012] In accordance, the present invention relates to a method for assessing a hematological disease in a sample of a subject, said method comprising

[0013] (a) determining in said sample at least five, preferably at least six, more preferably at least seven, even more preferably at least eight, still more preferably at least nine, biomarkers selected from the list consisting of GNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, CCL5, HOPX, KLRD1, EFHD2, CD8A, CTSW, CST7, ITGB1, BHLHE40, LYAR, S100A4, GZMA, MXRA7, KLRK1, SH3BGRL3, ITGA4, FCRL6, TGFB1, CCL4, ZEB2, AOAH, AHNAK, S100A10, LGALS1, PRF1, ITGB2, CD52, TPST2, PRSS23, ANXA1, CYBA, C12orf75, LAIR2, MATK, S100A6, TNFAIP3, CLIC1, KLF6, C1orf21, SYNE2, HLA-DPB1, HLA-DPA1, DSTN, CD99, TAGLN2, PLEK, LINC02446, RPS26, RGCC, NFKBIA, FOS, PPP2R5C, CRIP1, AKAP13, ZFP36, and FLNA; and

[0014] (B) thereby assessing said hematological disease.

[0015] In general, terms used herein are to be given their ordinary and customary meaning to a person of ordinary skill in the art and, unless indicated otherwise, are not to be limited to a special or customized meaning. As used in the following, the terms “have”, “comprise” or “include” or any arbitrary grammatical variations thereof are used in a non-exclusive way. Thus, these terms may both refer to a situation in which, besides the feature introduced by these terms, no further features are present in the entity described in this context and to a situation in which one or more further features are present. As an example, the expressions “A has B”, “A comprises B”, and “A includes B” may all refer to a situation in which, besides B, no other element is present in A (i.e. a situation in which A solely and exclusively consists of B), but also to a situation in which, besides B, one or more further elements are present in entity A, such as element C, elements C and D or even further elements. Also, as is understood by the skilled person, the expressions "comprising a" and "comprising an" preferably refer to "comprising one or more", i.e. are equivalent to "comprising at least one". In accordance, expressions relating to one item of a plurality, unless otherwise indicated, preferably relate to at least one such item, preferably a plurality thereof; thus, e.g. determining "a biomarker" relates to identifying at least one biomarker, preferably to identifying a multitude of biomarkers. Also, the term "plurality" relatesDeutsches Krebsforschungszentrum 3 DK17411PC Stiftung des öffentlichen Rechts et al.

[0016] to a multitude, preferably at least two, more preferably at least three, still more preferably at least four, of the indicated items, unless indicated otherwise.

[0017] Further, as used in the following, the terms "preferably", "more preferably", "most preferably", "particularly", "more particularly", "specifically", "more specifically", "typically", or similar terms are used in conjunction with optional features, without restricting further possibilities. Thus, features introduced by these terms are optional features and are not intended to restrict the scope of the claims in any way. The invention may, as the skilled person will recognize, be performed by using alternative features. Similarly, features introduced by "in an embodiment" or similar expressions are intended to be optional features, without any restriction regarding further embodiments of the invention, without any restrictions regarding the scope of the invention, and without any restriction regarding the possibility of combining the features introduced in such way with other optional or non-optional features of the invention.

[0018] The methods specified herein, preferably, are in vitro methods, preferably ex vivo methods. Some methods or steps thereof, may, however also be performed in vivo. The method steps may, in principle, be performed in any arbitrary sequence deemed suitable by the skilled person, but preferably are performed in the indicated sequence; also, one or more, preferably all, of said steps may be assisted or performed by automated equipment. Moreover, the methods may comprise steps in addition to those explicitly mentioned above. Also, the methods may be comprised in other methods; e.g. the method for assessing a hematological disease may be comprised in a method of monitoring a subject, e.g. during ongoing immunotherapy. Also, the methods are preferably at least partially, preferably fully, computer-implemented, wherein the term “computer-implemented”, as used herein, preferably means that the method is carried out at least partially in an automated fashion directed by a data processing unit which is, typically, comprised in a computer or similar data processing device, such as an evaluation device as described herein below. The data processing device shall obtain results of determining the at least five biomarkers, e.g. values for the amounts of the at least five biomarkers. Such values can be the amounts, relative amounts or any other calculated value reflecting amounts as described elsewhere herein in detail. Accordingly, it is to be understood that the methods described herein do not necessarily require the determination of amounts for the biomarkers but rather may use values of amounts determined earlier, which may e.g. be obtained from a storage means and / or from a database. As the skilled person understands, however, it is preferred that such values determined earlier were preferably determined at most 1 month, more preferably atDeutsches Krebsforschungszentrum 4 DK17411PC Stiftung des öffentlichen Rechts et al.

[0019] most 2 weeks, still more preferably at most 1 week, before a method described herein is performed, i.e. the values determined earlier preferably are the values of the most recent determination performed for the subject.

[0020] Basic statistic tools are known in the art. Thus, whether a portion of a population or a feature is statistically significant can be determined without further ado by the person skilled in the art using various well known statistic evaluation tools, e.g., determination of confidence intervals, p-value determination, Student's t-test, Mann-Whitney test etc. Details are found in textbooks, such as Dowdy and Wearden, Statistics for Research, John Wiley & Sons, New York 1983. Preferred confidence intervals are at least 95%, at least 97%, at least 98% or at least 99 %. The p-values are, preferably, 0.05, 0.01, 0.005, or 0.0001.

[0021] As used herein, if not otherwise indicated, the term "about" relates to the indicated value with the commonly accepted technical precision in the relevant field, preferably relates to the indicated value ± 20%, preferably ± 10%, preferably ± 5%. Further, the term "essentially" indicates that deviations having influence on the indicated result or use are absent, i.e. potential deviations do not cause the indicated result to deviate by more than ± 20%, preferably ± 10%, preferably ± 5%. Thus, “consisting essentially of’ means including the components specified but excluding other components except for materials present as impurities, unavoidable materials present as a result of processes used to provide the components, and components added for a purpose other than achieving the technical effect of the invention. For example, a composition defined using the phrase “consisting essentially of’ encompasses any known acceptable additive, excipient, diluent, carrier, and the like. Preferably, a composition consisting essentially of a set of components will comprise less than 5% by weight, preferably less than 3% by weight, preferably less than 1% by weight, preferably less than 0.1% by weight of non-specified component(s).

[0022] The term “polynucleotide", as used herein, refers to a linear or circular nucleic acid molecule. The polynucleotide of the present invention shall be provided, preferably, either as an isolated polynucleotide (i.e. isolated from its natural context) or in genetically modified form, preferably comprising at least one heterologous sequence. The term polynucleotide encompasses single-as well as, partially or completely, double-stranded polynucleotides. Preferably, the polynucleotide is a DNA polynucleotide, which may also be referred to as " DNA“. Moreover, comprised are also chemically modified polynucleotides including naturally occurring modifiedDeutsches Krebsforschungszentrum 5 DK17411PC Stiftung des öffentlichen Rechts et al.

[0023] polynucleotides such as glycosylated or methylated polynucleotides or artificially modified derivatives such as biotinylated polynucleotides, locked nucleic acids, peptide nucleic acids, and the like. In view of the description herein, template DNA, e.g. for PCR, primers, e.g. sequencing or amplification primers, and probe oligonucleotides are included in the term polynucleotide.

[0024] Unless specifically indicated otherwise, reference to specific polynucleotides herein preferably includes polynucleotide variants. The term “polynucleotide variant", as used herein, relates to a variant of a polynucleotide referred to herein comprising a nucleic acid sequence characterized in that the sequence can be derived from the aforementioned specific nucleic acid sequence by at least one nucleotide substitution, addition and / or deletion, wherein the polynucleotide variant shall have the function and / or activity as specified for the specific polynucleotide. The polynucleotide variant may also be or be derived from a mutant of the specific polynucleotide, preferably a naturally occurring mutant. Also preferably, said polynucleotide variant is or is derived from a non-naturally occurring allele of the specific polynucleotide. Further polynucleotide variants include polynucleotides comprising nucleic acid sequences which are at least 70%, preferably at least 80%, preferably at least 90%, preferably at least 95%, preferably at least 98%, preferably at least 99%, identical to the specifically indicated nucleic acid sequences. The percent identity values are, preferably, calculated over the entire nucleic acid sequence region, preferably as specified herein elsewhere. The polynucleotides of the present invention either consist of, essentially consist of, or comprise the aforementioned nucleic acid sequences. Thus, they may contain further nucleic acid sequences as well.

[0025] The term "protein" is understood by the skilled person; preferably, the protein comprises at least one amino acid chain, i.e. a polypeptide as specified herein below, preferably comprises a multitude of polypeptides. Thus, the protein may be a multimer, e.g. a dimer, a trimer, or the like, wherein the polypeptides in the multimer may be connected covalently, e.g. by a disulfide bridge, or non-covalently, e.g. by ionic interactions, hydrophobic interactions, and / or van der Waals interactions. The protein may consist of identical polypeptides, e.g. may be a homodimer, or may comprise at least two non-identical polypeptides, e.g. may be a heterodimer. Preferably, the protein as specified comprises all structural components as indicated comprised in one continuous covalent polypeptide chain, thus, the protein preferably is, or is comprised in, a fusion polypeptide.Deutsches Krebsforschungszentrum 6 DK17411PC Stiftung des öffentlichen Rechts et al.

[0026] The term “polypeptide”, as used herein, refers to a molecule consisting of a multitude of amino acids, preferably L-amino acids, that are covalently linked to each other by peptide bonds. Polypeptides consisting of less than 20 amino acids covalently linked by peptide bonds may also be referred to as "peptides". Preferably, the polypeptide comprises of from 100 to 1000, preferably of from 150 to 1000, preferably of from 200 to 500, preferably of from 250 to 400 amino acids. The polypeptide may also be comprised in a fusion polypeptide, i.e. may comprise amino acid sequences in addition to those specifically indicated. Also, the polypeptide may comprise additional, non-peptidic structures, such as at least one glycosylation, lipid conjugation, and the like. Thus, unless specifically indicated otherwise, reference to specific polypeptides herein preferably includes polypeptide variants.

[0027] As used herein, the term "polypeptide variant" relates to any chemical molecule comprising at least one polypeptide as specified herein differing in structure from a specifically indicated polypeptide. Preferably, the polypeptide variant comprises a contiguous amino acid sequence corresponding to at least 70%, preferably at least 80%, preferably at least 90%, preferably at least 95%, preferably at least 98%, preferably at least 99%, of the amino acid sequence of the polypeptide specifically indicated. Moreover, it is to be understood that a polypeptide variant as referred to in accordance with the present invention shall have an amino acid sequence which differs due to at least one amino acid substitution, deletion and / or addition, wherein the amino acid sequence of the variant is still, preferably, at least 70%, preferably at least 80%, preferably at least 90%, preferably at least 95%, preferably at least 98%, preferably at least 99%, identical with the amino acid sequence of the specific polypeptide. The degree of identity between two amino acid sequences can be determined by algorithms well known in the art and as described herein elsewhere. Polypeptide variants referred to above may be allelic variants or any other species specific homologs, paralogs, or orthologs. Moreover, the polypeptide variants referred to herein include fragments of the specific polypeptides or the aforementioned types of polypeptide variants, preferably as long as these fragments and / or variants have the activity as specified, e.g. immunogenicity in the case of epitopes or polypeptides comprising them. Such fragments may be or may be derived from, e.g., degradation products or splice variants of the polypeptides. Further included are variants which differ due to posttranslational modifications such as phosphorylation, glycosylation, ubiquitinylation, sumoylation, or myristylation, by including non-natural amino acids, and / or by being peptidomimetics.Deutsches Krebsforschungszentrum 7 DK17411PC Stiftung des öffentlichen Rechts et al.

[0028] The term "fragment" of a biological macromolecule, preferably of a polynucleotide or polypeptide, is used herein in a wide sense relating to any sub-part, preferably subdomain, of the respective biological macromolecule comprising the indicated sequence, structure and / or activity. Thus, the term includes sub-parts generated by actual fragmentation of a biological macromolecule, but also sub-parts derived from the respective biological macromolecule in an abstract manner, e.g. in silico.

[0029] The "activity" of a polynucleotide or polypeptide as specified herein is, preferably, preserved in the polynucleotide variant or polypeptide variant; as the skilled person will understand in view of the description herein, the activity of a polynucleotide or polypeptide does not necessarily have to reflect its main natural function, but may preferably be a further activity relevant in the context of the claimed invention. On a strictly exemplary basis, the GNLY polypeptide (granulysin) has an activity of being an antimicrobial peptide, but GNLY and its polypeptide variants also are immunogenic and are detectable by immunological means. Thus, a biomarker polypeptide, including a polypeptide variant and / or fragment thereof, preferably may have the activity of being detectable in an immunoassay for the purpose of the instant invention. The above applies to peptide variants and to protein variants mutatis mutandis. Similarly, an mRNA expressed from the GNLY gene has the activity of encoding a GNLY polypeptide, but also has the activity of being detectable e.g. by a probe oligonucleotide and being a surrogate marker of GNLY activity in a cell. Preferably, the activity of the polypeptide biomarkers and / or the polynucleotide biomarkers referred to herein is being indicative of expression of the corresponding gene encoding said biomarker, respectively. As the skilled person understands in view of the description herein, said gene expression preferably in turn is indicative of a physiological state of a subject.

[0030] The degree of identity (e.g. expressed as "%identity") between two biological sequences, preferably DNA, RNA, or amino acid sequences, can be determined by algorithms well known in the art. Preferably, the degree of identity is determined by comparing two optimally aligned sequences over a comparison window, where the fragment of sequence in the comparison window may comprise additions or deletions (e.g., gaps or overhangs) as compared to the sequence it is compared to for optimal alignment. The percentage is calculated by determining, preferably over the whole length of the polynucleotide or polypeptide as specified herein, the number of positions at which the identical residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positionsDeutsches Krebsforschungszentrum 8 DK17411PC Stiftung des öffentlichen Rechts et al.

[0031] in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman (1981), by the homology alignment algorithm of Needleman and Wunsch (1970), by the search for similarity method of Pearson and Lipman (1988), by computerized implementations of these algorithms (e.g. BLAST, GAP, BESTFIT, PASTA, or TFASTA), or by visual inspection. Given that two sequences have been identified for comparison, GAP and BESTFIT are preferably employed to determine their optimal alignment and, thus, the degree of identity. Preferably, the default values of 5.00 for gap weight and 0.30 for gap weight length are used. Preferably, the Basic Local Alignment Search Tool (BLAST) implementation is used with default parameter values for alignment. In the context of biological sequences referred to herein, the term "essentially identical" indicates a %identity value of at least 90%, preferably at least 95%, preferably at least 98%, preferably at least 99%. As will be understood, the term essentially identical includes 100% identity. The aforesaid applies to the term "essentially complementary" mutatis mutandis.

[0032] The term "hematological disease" is, in principle, understood by the skilled person. The term is used herein in a broad sense to relate to any disease affecting the blood system, including blood cell forming structures such as the bone marrow and the spleen, of a subject. Preferably, the hematological disease is a hematological neoplasia, more preferably a non-tumor forming cancer. More preferably, the hematological disease is selected from the list consisting of acute lymphoblastic leukemia; acute myeloid leukemia; AIDS-related lymphoma; Burkitt lymphoma; chronic lymphocytic leukemia; chronic myelogenous leukemia; hairy cell leukemia; Hodgkin lymphoma; Kaposi sarcoma; multiple myeloma and its precursor diseases, in particular monoclonal gammopathy of undetermined significance, smoldering myeloma, plasmocytoma, multiple myeloma, and plasma cell leukemia; mycosis fungoides; non-Hodgkin lymphoma; primary central nervous system lymphoma; Sezary syndrome; and Waldenstrom macroglobulinemia. More preferably, the hematological disease is a multiple myeloma or leukemia, preferably an acute myeloid leukemia (AML).

[0033] As referred to herein, a "immune responsive" form of hematological disease preferably is a form of hematological disease which is treatable, preferably by immunotherapy, wherein the term "treatable" relates to a form of hematological disease in which said treatment leads to at least one of stable disease, regression, and / or healing with regards to the hematological disease. Preferably, an immune responsive form of hematological disease after treatment, preferablyDeutsches Krebsforschungszentrum 9 DK17411PC Stiftung des öffentlichen Rechts et al.

[0034] after immunotherapy, has a 5-year survival rate of at least 2fold, preferably at 3fold, more preferably at least 4fold, the average 5 year survival rate of said hematological disease. Conversely, a "non-immune responsive" form of hematological disease preferably is an at least potentially life threatening form of hematological disease, in which disease typically progresses despite treatment, preferably despite immunotherapy. Thus, a non-immune responsive form of hematological disease preferably has a 5-year survival rate of less than Ifold, preferably at most O.5fold, more preferably at most O.3fold the average 5 year survival rate of said hematological disease. As the skilled person is aware of, survival rates depend on a multitude of factors, in particular type of hematological disease, staging, comobidities, and the like, so the aforesaid average 5 year survival rate preferably is the 5 year survival rate for the allocated to the aforesaid factors. As the skilled person understands in view of the description herein, immune responsive and non-immune responsive forms of hematological disease preferably are mutually exclusive only for a given point in time; i.e., a subject typically will, at a given point in time, be classified as suffering either from an immune responsive form or from a non-immune responsive form of hematological disease. However, an immune responsive form of hematological disease may precede in time a non-immune responsive form of disease, or, in case of successful therapy, a non-immune responsive form of hematological disease may precede in time an immune responsive form of disease. Thus, a subject suspected to be at risk of developing a non-immune responsive form of hematological disease may in particular be a subject suffering from an immune responsive form of disease at the time the method for assessing is performed.

[0035] The terms "treating" and “treatment” refer to measures taken to achieve an amelioration of the diseases or disorders referred to herein or the symptoms accompanied therewith to a significant extent. Said treating as used herein also includes an entire restoration of health with respect to the diseases or disorders referred to herein. It is to be understood that treating, as the term is used herein, may not be effective in all subjects to be treated. However, the term shall require that, preferably, a statistically significant portion of subjects suffering from a disease or disorder referred to herein can be successfully treated. Whether a portion is statistically significant can be determined without further ado by the person skilled in the art using various well known statistic evaluation tools, as specified herein above.

[0036] As referred to herein, treating also includes preventing deterioration of disease, i.e. preventing aggravation. The term “preventing aggravation” refers to retaining a given health status withDeutsches Krebsforschungszentrum 10 DK17411PC Stiftung des öffentlichen Rechts et al.

[0037] respect to the diseases or disorders referred to herein for a certain period of time in a subject. It will be understood that said period of time may be dependent on the type and quantity of treatment which has been administered and individual factors of the subject; also, preventing aggravation may require some time to take effect after a treatment is started, so preventing aggravation may e.g. not be effective in the first 2 weeks, preferably the first month, of treatment. It is also to be understood that prevention of aggravation may not be effective in all subjects treated. However, the term requires that, preferably, a statistically significant portion of subjects of a cohort or population are effectively prevented from aggravation of a disease or disorder referred to herein or its accompanying symptoms. Preferably, a cohort or population of subjects is envisaged in this context which normally, i.e. without preventive measures, would develop aggravation of a disease or disorder, in particular a non-immune responsive form of hematological disease, as referred to herein.

[0038] Preferably, treating comprises administration of at least one medical treatment to a subject, preferably immunotherapy and, optionally, chemotherapy. Immunotherapy may in particular be administered to a subject assessed to suffer from an immune responsive form of hematological disease as specified herein above, in case said therapy is assessed to probably be successful, in case a subject is assessed to comprise a sufficiently high number of reactive T cells, and the like. The term "immunotherapy", as used herein, relates to the treatment of hematological disease, preferably hematological neoplasia, by modulation of the immune response of a subject, preferably a cellular immune response, more preferably a T cell immune response. Said modulation may be inducing, enhancing, or suppressing said immune response, e.g. by administration of at least one immune checkpoint modulator and / or cytokine. Preferably, the cytokine is an interferon, an interleukin, or a chemokine in such case. The immunotherapy may also comprise administration of T cells, e.g. CAR T cells and / or recombinant T cell receptor T cells, and / or at least one T cell engager, i.e. a molecule tethering a T cell to a target cell; corresponding T cell engagers, e.g. bispecific T cell engagers (BiTEs) such as bispecific antibodies, or antibody-drug conjugates, are known in the art. Also, the immunotherapy may be or comprise allogenic or autologous stem cell transplantation. Preferably, the immunotherapy is combined with chemotherapy. Preferably, the immunotherapy comprises therapy with anti-CD38 antibodies, such as daratumumab or isatuximab, proteasome inhibitors, such as bortezomib or carfilzomib, and / or Cereblon E3 ligase modulators, also known as immunomodulatory imide drugs (IMiDs) such as lenalidomide, more preferably is a combined therapy with daratumumab, bortezomib, lenalidomide, and dexamethasone. Also preferably,Deutsches Krebsforschungszentrum 11 DK17411PC Stiftung des öffentlichen Rechts et al.

[0039] the immunotherapy comprises nivolumab therapy, preferably combined azacitidine and nivolumab therapy.

[0040] As used herein, the term "chemotherapy" relates to treatment of a subject with an antineoplastic drug. Preferably, chemotherapy is a treatment including alkylating agents (e.g. cyclophosphamide), platinum (e.g. carboplatin), anthracyclines (e.g. doxorubicin, epirubicin, idarubicin, or daunorubicin) and topoisomerase II inhibitors (e.g. etoposide, irinotecan, topotecan, camptothecin, or VP16), anaplastic lymphoma kinase (ALK)-inhibitors (e.g. Crizotinib or AP26130), aurora kinase inhibitors (e.g. N-[4-[4-(4-Methylpiperazin-l-yl)-6-[(5-methyl-lH-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide (VX-680)), anti angiogenic agents (e.g. Bevacizumab), Iodine131-1-(3-iodobenzyl)guanidine (therapeutic metaiodobenzylguanidine), Melphalan, BCL-2 inhibitors, such as Venetoclax, and / or IDH inhibitors, such as ivosidenib, alone or any suitable combination thereof. It is to be understood that chemotherapy, preferably, relates to a complete cycle of treatment, i.e. a series of several (e.g. four, six, or eight) doses of antineoplastic drug or drugs applied to a subject separated by several days or weeks without such application. Chemotherapy may also include immune ablation as a preparation for stem cell transplantation.

[0041] In case a subject is assessed to suffer from a non-immune responsive form of hematological disease as specified herein above, in case immunotherapy is assessed to probably not be successful, in case a subject is assessed to comprise an insufficiently high number of reactive T cells, and the like, treating preferably comprises standard cytostatic therapeutic regimens which do not specifically rely on the immune system.

[0042] The term “assessing”, as used herein, refers to establishing information about the status of the indicated disease or condition, in particular its severity, prognosis, treatment options, and / or other relevant information. As the skilled person understands in view of the description herein, the method of assessing described herein is an aid in determining the immune status of a subject with regard to the hematological disease, in particular the propensity of a subject's immune system to react to the hematological disease. Thus, the method of assessing preferably is an aid in determining whether a subject comprises T cells recognizing disease-mediating target cells, in particular cancer cells. Also preferably, the method of assessing is an aid in determining whether a subject comprises reactive T cells recognizing disease-mediating cells, in particular cancer cells. The determination may be based on the aforesaid assessment, however, preferablyDeutsches Krebsforschungszentrum 12 DK17411PC Stiftung des öffentlichen Rechts et al.

[0043] is based on the aforesaid assessment and further diagnostic information, such as anamnesis data, general physical and / or mental examination findings, and / or additional metabolic data. Moreover, assessing hematological disease may further include assessing whether a subject is at risk of suffering from hematological disease, exhibits a medical condition which deteriorates with respect to hematological disease, and / or establishing a prognosis with respect to hematological disease. Thus, assessing preferably comprises prognosticating the hematological disease, monitoring hematological disease therapy, predicting outcome of a pre-determined hematological disease therapy, predicting hematological disease relapse, assessing whether a subject is susceptible to a pre-determined hematological disease therapy, and / or establishing a recommendation for hematological disease therapy of a subject. Preferably, the method of assessing as such does not lead to a diagnosis of hematological disease.

[0044] In accordance with the above, assessing as used herein preferably includes diagnosing severity of hematological disease, predicting the risk for developing hematological disease, and / or predicting any deterioration of the health condition of the subject, in particular, with respect to signs and symptoms accompanying hematological disease. Thus, the method as specified may in particular be comprised in a method of monitoring hematological disease and / or monitoring hematological disease treatment. Assessment referred to herein may also be the assessment of a risk of developing hematological disease, preferably a risk of developing non-immune responsive hematological disease. Preferably, assessment is the prediction of the risk that a subject’s health condition will deteriorate. Moreover, it will be understood that if the risk of developing hematological disease or risk of the deterioration of the health condition is predicted, typically, the prediction is made within a predictive window. More typically, said predictive window is of from 1 week to 5 years, preferably of from 1 month to 1 year.

[0045] Preferably, assessing comprises providing a surrogate marker of a presence and / or quantification of T cells in a reactive status in a subject. The term "reactive" status in the context of T cells is understood by the skilled person; preferably, a reactive T cell recognizes an antigen, preferably an MHC-class I or an MHC class II epitope presented on a target cell, and is stimulated to secrete at least one of an interferon, preferably interferon-gamma, and an interleukin, preferably IL-2, by interaction of said T cell with said target cell. Moreover, assessing may also comprise determining T cell fitness, wherein the term T cell "fitness" relates to a propensity of a T cell to be reactive as specified herein above, as opposed to be in a state of anergy, quiescence or terminal exhaustion and, preferably showing no sign of functionalDeutsches Krebsforschungszentrum 13 DK17411PC Stiftung des öffentlichen Rechts et al.

[0046] activity towards tumor cells. Thus, assessing preferably comprises determining a T cell immune status in a subject, wherein the term " T cell immune status" relates to a measure of the propensity of T cells in a subject to be or become reactive as specified herein above. Also preferably, assessing comprises predicting a therapy success, in particular of an immunotherapy, preferably of a hematological disease. Thus, assessing in particular may comprise identifying a subject susceptible to immunotherapy and / or predicting immune mediated toxicity, preferably in said immunotherapy. The term "immune mediated toxicity" is known to the skilled person from medical textbooks; symptoms thereof include in particular Cytokine Release Syndrome (CRS), Immune-effector-cell associated Neurotoxicity (ICANS), Immune-effector-cell associated Hematotoxicity (ICAHT), as well as more general, skinrash, prutitus, diarrhea, dyspnea, myositis, autoimmune endocriopathies (such as Hypothyroidism, Hyperthyroidism, Adrenal insufficiency, Hypophysitis). Moreover, assessing preferably comprises immunotherapy monitoring, in particular identification of a presence and / or quantification of T cells in a reactive status over at least a part of the course of a therapy, in particular immunotherapy. Also, assessing may comprise aiding in deciding which type of immunotherapy shall be administered, e.g. whether a CAR therapy, a BiTE therapy, an immune checkpoint blockade (ICB) therapy, an immunochemotherapy, or an allogenic and autologous stem cell transplantation, or a combiation of any of the aforesaid, shall be administered.

[0047] As referred to herein, assessing hematological disease preferably may also refer to establishing information about differentiating between subtypes of hematological disease as specified herein below, i.e. said assessing preferably is an aid in differentially diagnosing the indicated disease subtypes; as the skilled person will understand, establishing a differential diagnosis may be based on the aforesaid assessment, however, preferably is based on the aforesaid assessment in combination with further diagnostic information, preferably as specified herein above. Thus, assessing hematological disease may relate to assessing whether a subject suffers from a first subtype of a hematological disease or a second subtype of said hematological disease. Accordingly, assessing as used herein includes classifying subtypes of hematological disease. Preferably, in particular in case of differentiating of subtypes of hematological disease, the subject was diagnosed to show at least one symptom shared by said subtypes. Thus, assessing preferably comprises assisting in triaging said subject, in particular assisting in determining whether said subject is susceptible to immunotherapy, or is not susceptible to immunotherapy. Thus, assessing preferably comprises assisting in identifying a subject benefiting from immunotherapy and / or assisting in identifying subject not benefiting from immunotherapy.Deutsches Krebsforschungszentrum 14 DK17411PC Stiftung des öffentlichen Rechts et al.

[0048] Assessing as referred to herein may relate to a rule-in assessment, i.e. to identifying a subject as belonging to a group of subjects sharing a common feature, e.g. as suffering from an immune responsive form of hematological disease. Assessing, however, may also relate to a rule-out assessment, i.e. to identifying a subject as not belonging to a group of subjects sharing a common feature, e.g. as not suffering from an immune responsive form of hematological disease. Thus, the assessment may aid in establishing a differential diagnosis and / or in triage. As the skilled person is aware of, e.g. excluding a non-immune responsive form of hematological disease in a subject showing symptoms thereof may be of help to decide on the further course of treatment.

[0049] As will be understood by those skilled in the art, the assessment made in accordance with the present invention, although usually preferred to be, may not be correct for 100% of the investigated subjects. However, the term typically requires that a statistically significant portion of subjects can be correctly assessed. Whether a portion is statistically significant can be determined without further ado by the person skilled in the art using various well known statistic evaluation tools, e.g., as specified herein above.

[0050] The term “sample”, as used herein, refers to a biological sample from a body fluid, preferably blood, plasma, serum, saliva or urine, or a sample derived from cells, tissues or organs, e.g., by biopsy, wherein said sample preferably is known or suspected to comprise T cells. Preferably, the sample is a blood or a blood-derived sample, preferably is a sample of peripheral blood monocytic cells (PBMCs), a sample of enriched T cells, a sample of bone marrow material, or the like. Preferably, the sample is a sample of CD45+ CD3+ cells enriched from a blood derived or bone marrow-derived sample". Biological samples can be derived from a subject by techniques known in the art. For example, blood samples may be obtained by blood taking, bone marrow sample can be obtained e.g. by aspiration, while tissue or organ samples are to be obtained, e.g., by biopsy. Preferably, the sample is known or suspected to comprise at least five of the biomarkers referred to herein. The aforementioned samples may be pre-treated before they are used according to the present invention. Said pre-treatment may include treatments required to release or separate the biomarker(s) and / or the analyte(s) or to remove excessive material or waste. Suitable techniques comprise centrifugation, extraction, fractioning, ultrafiltration, protein precipitation followed by filtration and purification and / or enrichment of compounds. Moreover, other pre-treatments may be carried out in order to provide theDeutsches Krebsforschungszentrum 15 DK17411PC Stiftung des öffentlichen Rechts et al.

[0051] biomarker and / or analyte in a form or concentration suitable for the intended determination. Suitable and necessary pre-treatments depend on the means used for carrying out the methods of the invention and are well known to the person skilled in the art. Pre-treated samples as described before are also comprised by the term “sample” as used in accordance with the present invention.

[0052] The term “subject”, as used herein, relates to a vertebrate animal, preferably to a mammal. Preferably, the subject is a primate and, more preferably, a human. The subject may be an apparently healthy subject, however, preferably, is a subject known or suspected to suffer from hematological disease. Preferably, the subject known or suspected to suffer from hematological disease is a subject showing symptoms of hematological disease, in particular hematological neoplasia. Preferably, the subject is a subject in need of differential diagnosis of hematological disease. Thus, the subject preferably is a subject showing at least one symptom of subtypes of hematological disease, preferably as specified herein above.

[0053] The term "cell", as used herein, is understood by the skilled person as relating to the smallest structural unit in biology with the principal ability of self-replication. The cell preferably is a cell of a subject; thus, the cell preferably is a mammalian cell, more preferably a human cell. Preferably, the cell is a target cell. The term “target cell” relates to a cell known or suspected to mediate hematological disease and / or deemed desirable by the skilled person to remove from the body of a subject or from a population of cultured cells. Thus, the target cell may in particular be a disease-mediating cell, i.e. a cell contributing, directly or indirectly, to severity of a hematological disease and / or symptoms associated therewith. Preferably the target cell expresses at least MHC class I molecules and, optionally, MHC class II molecules. Also preferably, the target cell expresses an antigen and presents an epitope thereof recognized by a T cell of the subject. The aforesaid antigen preferably is a cancer antigen, wherein the term "cancer antigen" preferably relates to an antigen, preferably a polypeptide, expressed by a cancer cell. Preferably, the cancer antigen is expressed at an at least 5fold, preferably at least lOfold, more preferably at least 25fold, lower rate in non-cancer cells. Preferably, the cancer antigen is not expressed in non-tumor cells of the same tissue in a subject, more preferably is not expressed in non-cancer cells of a subject; thus, the cancer antigen preferably is a cancer specific antigen. More preferably, the cancer antigen is a neoantigen and / or comprises a neoepitope, expressed by cancer cells. Preferably, one or more peptides of the cancer antigen are presented via MHC molecules, more preferably MHC class I molecules, on the surface ofDeutsches Krebsforschungszentrum 16 DK17411PC Stiftung des öffentlichen Rechts et al.

[0054] target cells. Thus, the target cell preferably is a cancer cell. Preferably, the target cell is a cell of a subject or a cultured cell derived therefrom.

[0055] The term “biomarker”, as used herein, refers to a molecular species which serves as an indicator for an assessment as referred to herein. Said molecular species can be a metabolite itself which is found in a sample of a subject. Preferably, the biomarker is a gene product or a specific fragment thereof, in particular an RNA and / or polypeptide being the product of expression of said gene. Mechanisms of gene expression and their products are known to the skilled person from standard textbooks e.g. of cell biology. In case the biomarker, e.g. a polypeptide, has an activity, e.g. an enzymatic activity, the biomarker may also be said activity. Preferably, however, the gene product is an RNA being the product of gene expression, in particular an mRNA, or is a polypeptide, preferably produced by cells of the subject from the aforesaid mRNA. Moreover, the biomarker may also be a molecular species which is derived from the aforesaid metabolite, in particular a fragment thereof. The actual metabolite may be chemically modified in the sample or during the determination process and, as a result of said modification, a chemically different molecular species may be determined as the actual "analyte". Preferred chemical modifications may depend on the analytical method used and are described elsewhere herein. It is to be understood that the analyte represents the actual metabolite and has the same potential as an indicator for the respective medical condition. Moreover, a biomarker according to the present invention is not necessarily corresponding to one molecular species. Rather, the biomarker may comprise derivatives, such as one or more splice variants, a polypeptide product of at least one splice variant, and / or fragments of a compound. Further, a biomarker can also represent the sum of variants of a gene product. Said variants may exhibit identical analytical characteristics in some cases and may, therefore, not be distinguishable by some analytical methods including those applied in the accompanying Examples described below. Thus, e.g. in single-cell sequencing, all RNA molecules comprising a nucleic acid sequence to which a selected primer anneals may be detected, irrespective of whether the RNA is a full-length mRNA, a nuclear precursor, a splice variant, or a fragment of an mRNA. Also, e.g. in an immunoassay, a polypeptide may be detected as a gene product, but also any fragment or isoform of said polypeptide having the required epitope or epitopes may be detected. The biomarkers suitable for the assessment according to the present invention are described herein in Table 1.Deutsches Krebsforschungszentrum 17 DK17411PC Stiftung des öffentlichen Rechts et al.

[0056] The term “determining”, as used herein, refers to quantitatively determining a biomarker by measuring at least one characteristic feature of the analyte to be determined in a sample. Characteristic features in accordance with the present invention are features which characterize the physical and / or chemical properties including biochemical properties of an analyte. Such properties include, e.g., molecular weight, as e.g. determined by mass spectrometry; nucleic acid sequence, as e.g. determined by sequencing; capability to react with other compounds, in particular hybridization to one or more probe oligonucleotide or primer oligonucleotide(s), or immunological reactivity; capability to elicit a response in a biological read out system (e.g., induction of a reporter gene); and the like. Values for the aforesaid properties may serve as characteristic features and can be determined by techniques well known in the art. Moreover, the characteristic feature may be any feature which is derived from the values of the physical and / or chemical properties of a biomarker by standard operations, e.g., mathematical calculations such as multiplication, division or logarithmic calculus. Most preferably, the at least one characteristic feature allows the determination and / or chemical identification of the biomarker and its amount. Accordingly, the characteristic value, preferably, also comprises information relating to the abundance of the biomarker from which the characteristic value is derived. For example, a characteristic value of a biomarker may be a peak in a mass spectrum. Such a peak contains characteristic information of the biomarker, i.e. the m / z information, as well as an intensity value being related to the abundance of the said biomarker (i.e. its amount) in the sample.

[0057] A biomarker comprised by a sample may, in principle, be determined quantitatively or semi-quantitatively, preferably is determined quantitatively. For quantitative determination, either the absolute or precise amount of the biomarker will be determined or the relative amount of the biomarker will be determined based on the value determined for the characteristic feature(s) referred to herein above. The relative amount may be determined in a case where the precise amount of a biomarker can or shall not be determined. In said case, it can preferably be determined whether the amount in which the biomarker is present is increased or reduced with respect to a second sample comprising said biomarker in a second amount, or is increased or reduced with respect to a non-biomarker metabolite, such as e.g. a product of a housekeeping gene. Quantitatively analyzing a biomarker, thus, also includes what is sometimes referred to as semi -quantitative analysis of a biomarker. As is understood by the skilled person, the above applies to other measures of an amount of a compound, in particular a concentration, mutatis mutandis.Deutsches Krebsforschungszentrum 18 DK17411PC Stiftung des öffentlichen Rechts et al.

[0058] Preferably, a biomarker is determined by a specific chemical or biological assay. Said assay shall comprise means which allow to specifically detect the biomarker in the sample. Preferably, said means are capable of specifically recognizing the chemical structure of the biomarker ("detection agents") or are capable of specifically identifying the biomarker based on its capability to react with other compounds or its capability to elicit a response in a biological read out system (e.g., induction of a reporter gene). Means which are capable of specifically recognizing the chemical structure of a biomarker are, preferably, antibodies or other proteins which specifically interact with chemical structures, such as receptors or enzymes, or aptamers. Antibodies as referred to herein include both polyclonal and monoclonal antibodies, as well as fragments thereof, such as Fv, Fab and F(ab)2 fragments that are capable of binding the antigen or hapten. Moreover, encompassed are single chain antibodies and nanobodies. Suitable antibody and / or enzyme based assays may be RIA (radioimmunoassay), ELISA (enzyme-linked immunosorbent assay), sandwich enzyme immune tests, electrochemiluminescence sandwich immunoassays (ECLIA), dissociation-enhanced lanthanide fluoro immuno assay (DELFIA) or solid phase immune tests, in particular antibody arrays; e.g. at least five antibodies recognizing biomarkers as specified herein may be provided as an antibody array. As is understood by the skilled person, correspondingly at least five probe oligonucleotides hybridizing to biomarker RNAs may be provided as oligonucleotide array. Moreover, the biomarker may also be determined based on its capability to react with other compounds, i.e. by a specific chemical reaction.

[0059] Preferably, the detection agent binds specifically to the biomarker. Specific binding, as referred to herein, means that the detection agent should essentially not bind to (“cross-reacf ’ or "crosshybridize" with) another polypeptide or polynucleotide, i.e. any non-biomarker compound present in the sample to be analyzed. Preferably, the specifically bound biomarker should be bound with at least 3 times higher, more preferably at least 10 times higher, most preferably at least 50 times higher, affinity than any other relevant molecules. Specific determination is preferably performed with an assay above the assay's detection limit, wherein said detection limit preferably is selected such that at the detection limit, the signal generated by a sample comprising the biomarker provides for a signal at least 3 times the signal of a sample not comprising said biomarker. Nonetheless, non-specific binding may be tolerable if the biomarker can still be distinguished and measured unequivocally, e.g. according to its size on a Northern, Southern, or Western Blot, or by its relatively much higher, preferably at least 5fold higher,Deutsches Krebsforschungszentrum 19 DK17411PC Stiftung des öffentlichen Rechts et al.

[0060] signal compared to interferents in the sample. Measurement of the binding of a ligand may be performed by an analyzer unit of a system disclosed herein. Thereafter, an amount of the measured binding may be calculated by a computing device of a system disclosed herein.

[0061] Preferably, the biomarkers are determined as polynucleotides, in particular mRNA, or cDNA derived therefrom. As described herein in the Examples, the biomarkers may in particular be determined by single-cell RNA sequencing. However, any other method deemed appropriate by the skilled person may be used, e.g. sequencing of bulk RNA, hybridization of bulk RNA to suitable probe oligonucleotides, and the like.

[0062] The term "amount" is used herein a broad sense including each and every measure of quantity deemed appropriate by the skilled person. Thus, the amount may be an absolute amount, e.g. in a sample or in a defined volume of sample, a relative amount, e.g. as compared to one or more reference amount(s) and / or to one or more calibration amount(s), a concentration, preferably an absolute concentration, a relative concentration, or any value or parameter which correlates thereto or can be derived therefrom, preferably by standard mathematical operations. Such values or parameters comprise intensity signal values from all specific physical or chemical properties obtained from the biomarker during determining as specified herein. It is to be understood that values correlating to the aforementioned amounts or parameters can also be obtained by all standard mathematical operations.

[0063] As the skilled person is aware of, it may, however, not be necessary to express an amount in terms of quantity of material; the amount may also be expressed as a signal intensity in an assay, e.g. as read counts, as intensity of a fluorescent signal, as ECL units, as counts of radioactivity, as an area of an MS peak, or even as arbitrary units. As the skilled person will understand, measures not directly indicating amounts or concentrations may in particular be used in case all relevant values of amounts are expressed by the same measure. Preferably, determining an amount is performed as described herein elsewhere, preferably by the system described herein, whereby an analytic device determines the amount based on contacting and measuring steps described.

[0064] The method for assessing comprises step (a) determining in said sample at least five, preferably at least six, more preferably at least seven, even more preferably at least eight, still more preferably at least nine, biomarkers selected from the list consisting ofDeutsches Krebsforschungszentrum 20 DK17411PC Stiftung des öffentlichen Rechts et al.

[0065] GNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, CCL5, HOPX, KLRD1, EFHD2, CD8A, CTSW, CST7, ITGB1, BHLHE40, LYAR, S100A4, GZMA, MXRA7, KLRK1, SH3BGRL3, ITGA4, FCRL6, TGFB1, CCL4, ZEB2, AOAH, AHNAK, S100A10, LGALS1, PRF1, ITGB2, CD52, TPST2, PRSS23, ANXA1, CYBA, C12orf75, LAIR2, MATK, S100A6, TNFAIP3, CLIC1, KLF6, C1orf21, SYNE2, HLA-DPB1, HLA-DPA1, DSTN, CD99, TAGLN2, PLEK, LINC02446, RPS26, RGCC, NFKBIA, FOS, PPP2R5C, CRIP1, AKAP13, ZFP36, and FLNA.

[0066] Preferably, said at least five biomarkers comprise the biomarkers GNLY, ZNF683, GZMH, FGFBP2, and GZMB. Also preferably, step (a) comprises determining at least ten, preferably at least eleven, more preferably at least twelve, even more preferably at least 13, still more preferably at least 14, of the aforesaid biomarkers; more preferably, said biomarkers comprise the biomarkers GNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, CCL5, HOPX, KLRD1, and EFHD2. Also preferably, step (a) comprises determining at least 15, preferably at least 20, more preferably at least 30, even more preferably at least 40, still more preferably at least 50, most preferably all, biomarkers; more preferably, said biomarkers comprise the biomarkers GNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, CCL5, HOPX, KLRD1, EFHD2, CD8A, CTSW, CST7, ITGB1, and BHLHE40, still more preferably comprise the biomarkers GNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, CCL5, HOPX, KLRD1, EFHD2, CD8A, CTSW, CST7, ITGB1, BHLHE40, LYAR, S100A4, GZMA, MXRA7, and KLRK1, also more preferably comprise the biomarkers GNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, CCL5, HOPX, KLRD1, EFHD2, CD8A, CTSW, CST7, ITGB1, BHLHE40, LYAR, S100A4, GZMA, MXRA7, KLRK1, SH3BGRL3, ITGA4, FCRL6, TGFB1, CCL4, ZEB2, AOAH, AHNAK, S100A10, and LGALS1, also more preferably comprise the biomarkers GNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, CCL5, HOPX, KLRD1, EFHD2, CD8A, CTSW, CST7, ITGB1, BHLHE40, LYAR, S100A4, GZMA, MXRA7, KLRK1, SH3BGRL3, ITGA4, FCRL6, TGFB1, CCL4, ZEB2, AOAH, AHNAK, S100A10, LGALS1, PRF1, ITGB2, CD52, TPST2, PRSS23, ANXA1, CYBA, C12orf75, LAIR2, and MATK; also more preferably comprise the biomarkers GNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, CCL5, HOPX, KLRD1, EFHD2, CD8A, CTSW, CST7, ITGB1, BHLHE40, LYAR, S100A4, GZMA, MXRA7, KLRK1, SH3BGRL3, ITGA4, FCRL6, TGFB1, CCL4, ZEB2, AOAH, AHNAK, S100A10, LGALS1, PRF1, ITGB2, CD52, TPST2, PRSS23, ANXA1, CYBA, C12orf75, LAIR2, MATK, S100A6, TNFAIP3, CLIC1, KLF6, C1orf21, SYNE2, HLA-DPB1, HLA-DPA1, DSTN, and CD99. Most preferably, the biomarkers comprise the biomarkers GNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, CCL5, HOPX, KLRD1, EFHD2, CD8A, CTSW,Deutsches Krebsforschungszentrum 21 DK17411PC Stiftung des öffentlichen Rechts et al.

[0067] CST7, ITGB1, and BHLHE40. The aforesaid biomarkers and methods for determining them have been described herein above. Preferably, the methods described herein comprise determining biomarkers from the aforesaid list as the only biomarkers determined; also preferably, the methods described herein comprise determining the biomarker combinations indicated herein above as the only biomarkers determined. Also preferably, the methods comprise determining at most 63 biomarkers, more preferably at most 40 biomarkers, even more preferably at most 20 biomarkers, most preferably at most 15 biomarkers.

[0068] Preferably, step (a) comprises determining said biomarkers by single-cell gene expression measurement, preferably comprising determining said biomarkers and at least one housekeeping gene, and / or comprises determining a multitude of at least 100, preferably at least 200, more preferably at least 1000, non-biomarker genes. As the skilled person understands, expression of biomarkers is preferably compared to expression of at least one gene known to have an essentially constant expression in all cells and / or all cell states, preferably in order to normalize biomarker expression. As the skilled person understands in view of the description herein, biomarker expression may also be compared to expression of a multitude of genes in a cell, since with a number of genes sufficiently high, changes of gene expression are expected to mutually compensate each other. As an alternative or in addition, if expression of a multitude of non-biomarker genes is determined, expression of biomarker genes may be ranked within the expression levels of said non-biomarker genes, as described herein in the Examples.

[0069] Preferably, step (a) comprises step (al) determining expression of said biomarkers in said sample relative to at least one reference on a single-cell level (cell score). Also preferably, step (a) comprises step (a2) determining reactivity, proportion and / or absolute number of reactive T cells within at least one T cell clone of said sample (clone score), preferably based on a plurality of cell scores determined according to step (al). Also preferably, step (a) comprises step (a3) determining a score indicative of clone number and / or clone reactivity in a subject (patient score), preferably based on a plurality of clone scores determined according to step (a2) and / or a plurality of cell scores determined according to step (al). Preferably, said patient score comprises at least one parameter selected from the list consisting of number of reactive clones, fraction of reactive clones of all clones analyzed, average clone score of reactive clones, size of reactive clones, and sum of clone scores of reactive clones.Deutsches Krebsforschungszentrum 22 DK17411PC Stiftung des öffentlichen Rechts et al.

[0070] The method for assessing further comprises step (b) thereby assessing said hematological disease. Means and methods for assessing hematological disease have been described herein above. Preferably, assessing comprises determining further diagnostic information, preferably anamnesis data, general physical and / or mental examination findings, and / or additional metabolic data. Methods for providing further diagnostic information are known in the art from medical textbooks. In case the hematological disease is a hematological neoplasia, it may be beneficial to diagnose hematological neoplasia before performing step (a) and / or (b). The additional diagnostic information described above may be provided before, concomitant to, or following step (b), preferably may be provided before or concomitant to step (b).

[0071] Optionally, the method for assessing further comprises the further step of comparing the biomarkers determined in step (a) to at least one reference and assessing said hematological disease in step (b) based on said comparing, as described herein above.

[0072] The term “comparing” as used herein encompasses comparing a value, e.g. an amount, determined for a biomarker as referred to herein to a reference. It is to be understood that comparing as used herein refers to any kind of comparison made between the value for the amount with the reference. However, it is to be understood that preferably identical types of values are compared with each other, e.g., if an absolute amount is determined, the reference shall also be an absolute amount, if a relative amount is determined, the reference shall also be a relative amount, etc. The aforesaid comparison of identical types of values may also be referred to as comparing to a "corresponding" value, e.g. a corresponding reference, herein. The term comparing also encompasses comparing a calculated score with a suitable reference core. Thus, preferably, the corresponding reference is a value of the quantitative parameter allowing the assessment to be made.

[0073] The term “reference”, as used herein, relates to a value, e.g. an amount or any value derived therefrom, e.g. a score, which can be correlated to a medical condition and, preferably, which allows for the assessment as referred to herein to be made, preferably enables allocation of a subject into one of a multitude of groups of subjects with regards to hematological disease. Such a reference can be a threshold value, e.g. a threshold amount, which separates these groups from each other. Accordingly, the reference may be a value which allows for allocation of a subject into a group of subjects suffering from an immune responsive form of disease, or not. The reference may, however, also be a reference range, e.g., preferably, a range of values forDeutsches Krebsforschungszentrum 23 DK17411PC Stiftung des öffentlichen Rechts et al.

[0074] which an immune responsive form of hematological disease may be assessed to be present in a subject. Furthermore, the reference may be a value calculated from the aforesaid values, e.g. from two or more biomarkers, preferably to provide a score, e.g. a predictor score. A suitable reference separating the two groups can be provided without further ado e.g. by the statistical tests referred to herein elsewhere based on values of biomarkers from suitable reference groups as specified herein below. As the skilled person understands, it may not always be possible, although preferred, to provide a reference unambiguously allocating each and every possible value of a biomarker to one of the aforesaid groups; thus, there may be a range of values for which a clear assessment cannot be provided. Preferably, however, as indicated above, a reference enables the assessment to be made for each and every value of a biomarker or set of biomarkers which may be measured. As the skilled person understands, the specific value of a reference may depend on the assessment intended and on parameters thereof; thus, e.g. the reference for a differential diagnosis between two subtypes of hematological disease may be different from the reference for diagnosing hematological disease and from the reference for predicting deterioration of hematological disease. Relevant parameters having an influence on the reference may in particular be sensitivity and specificity of assessment.

[0075] A reference may in particular be derived from at least one reference group, the term "reference group" relating to a group of subjects with known status with regard to the assessment. Thus, the reference group may e.g. be a group of subjects for which it is known whether they suffer from an immune responsive form of hematological disease. The population of subjects in a reference group preferably comprises a plurality of subjects, e.g. at least 5, 10, 50, 100, 1,000, or 10,000 subjects. Typically, the subject to be diagnosed and the subjects of the said reference group are of the same species. The reference applicable for an individual subject may vary depending on various physiological parameters such as age, gender, or subpopulation. As is understood by the skilled person, in case prevalence of a disease in the population is low, e.g. at most 5%, preferably at most 1%, a reference may also be derived from the average population. Assuming that contribution of actually afflicted subjects is low, such an average population reference group may be treated as a reference group known not to suffer from hematological disease; preferably, in such case, the size of the reference group is sufficiently high, e.g. at least 100, more preferably at least 1000, still more preferably at least 10000 subjects. In view of the description herein, the skilled person understands that a reference group may, in principle, also be a mixed population of subjects with regard to hematological disease, provided that the status of each member of said mixed population in regard to hematologicalDeutsches Krebsforschungszentrum 24 DK17411PC Stiftung des öffentlichen Rechts et al.

[0076] disease is or becomes known before deriving a reference from such group. Also, a reference group may be a group of subjects known to suffer from the hematological disease, preferably a subtype thereof. A reference may, however, also be obtained from the subject under investigation, if available, e.g. from a sample taken earlier in time, preferably before the onset of symptoms of hematological disease.

[0077] Preferably, the reference is derived from at least one subject known to suffer from a non-immune responsive form of hematological disease, wherein in case the amount of biomarker is essentially the same or lower than said reference, it is assessed that the subject has a high probability of suffering from a non-immune responsive form of said hematological disease; and / or in case the amount of biomarker is higher than said reference, it is assessed that the subject has a low probability of suffering from a non-immune responsive form of said hematological disease. Preferably, the reference is derived from at least one subject known to suffer from an immune responsive form of said hematological disease or from at least one apparently healthy subject, and in case the amount of biomarker is essentially the same or higher than said reference, it is assessed that the subject has a high probability of suffering from an immune responsive form of said hematological disease; and / or in case the amount of biomarker is lower than said reference, it is assessed that the subject has a low probability of suffering from an immune responsive form of said hematological disease.

[0078] Reference amounts can, in principle, be calculated for a cohort of subjects based on the average or mean values for a given parameter such as biomarker amount by applying standard statistically methods. In particular, accuracy of a test such as a method aiming to diagnose an event, or not, is best described by its receiver-operating characteristics (ROC) (see especially Zweig 1993, Clin. Chem. 39:561-577). The ROC graph is a plot of all of the sensitivity / specificity pairs resulting from continuously varying the decision threshold, such as a reference value, over the entire range of data observed. The clinical performance of a diagnostic method depends on its accuracy, i.e. its ability to correctly allocate subjects to a certain prognosis or diagnosis. The ROC plot indicates the overlap between the two distributions by plotting the sensitivity versus 1 -specificity for the complete range of thresholds suitable for making a distinction. On the y-axis is sensitivity, or the true-positive fraction, which is defined as the ratio of number of true-positive test results to the product of number of true-positive and number of false-negative test results. This has also been referred to as positivity in the presence of a disease or condition. It is calculated solely from the affected subgroup. On theDeutsches Krebsforschungszentrum 25 DK17411PC Stiftung des öffentlichen Rechts et al.

[0079] x-axis is the false-positive fraction, or 1 -specificity, which is defined as the ratio of number of false-positive results to the product of number of true-negative and number of false-positive results. Each point on the ROC plot represents a sensitivity / -specificity pair corresponding to a particular decision threshold (i.e. reference). Qualitatively, the closer the plot is to the upper left corner, the higher the overall accuracy of the test. Dependent on a desired confidence interval, a threshold can be derived from the ROC curve allowing for the diagnosis or prediction for a given event with a proper balance of sensitivity and specificity, respectively. Dependent on a desired sensitivity and specificity for a diagnostic method, the ROC plot allows deriving suitable thresholds. It will be understood that an optimal sensitivity may be desired for excluding a subject for being at increased risk (i.e. a rule-out), whereas an optimal specificity may be envisaged for a subject to be assessed as being at an increased risk (i.e. a rule-in).

[0080] In view of the description herein, references are selected by the skilled person without further ado. Preferably, a reference is selected to represent the maximal value of the sum of the method’s sensitivity and specificity as specified by a ROC curve, e.g. as specified above and in the Examples. Preferably, the reference lies within the range of values that represent a sensitivity of at least 80% and a specificity of at least 65%, or a sensitivity of at least 80% and a specificity of at least 80%, or a sensitivity of at least 85% and a specificity of at least 65%, or a sensitivity of at least 85% and a specificity of at least 80%. However, the reference typically takes into account the clinical settings and requirements associated therewith, so significantly lower sensitivity and / or specificity values may be deemed acceptable by the skilled person; e.g., a low specificity of a differentiation a non-immune responsive form of disease from an immune responsive form of disease may be acceptable or even desirable in exchange for a high sensitivity.

[0081] Advantageously, it was found in the work underlying the present invention that the biomarkers described are particularly suitable to assess hematological disease as specified herein. In particular, the biomarkers allow for improved differentiation between subjects suffering from an immune responsive form of hematological disease from subjects suffering from a non-immune responsive form of said hematological disease. Thus, the biomarkers enable reliable therapy decision and / or prognostication of the aforesaid hematological diseases.Deutsches Krebsforschungszentrum 26 DK17411PC Stiftung des öffentlichen Rechts et al.

[0082] The definitions made above apply mutatis mutandis to the following. Additional definitions and explanations made further below also apply for all embodiments described in this specification mutatis mutandis.

[0083] The present invention also relates to a method for determining T cell reactivity in a sample comprising

[0084] (i) of the method for assessing a hematological disease described herein; and

[0085] (ii) determining T cell reactivity based on the result of step (i).

[0086] The method for determining T cell reactivity preferably is an in vitro method and is preferably performed on a sample of cells cultured in vitro. The parameter(s) used for determining T cell reactivity in step (ii) preferably are the same as described for the method for assessing a hematological disease described herein above.

[0087] Also, the present invention relates to a method for stratifying subjects according to their T cell reactivity, comprising

[0088] (I) determining in samples from said subjects at least five biomarkers according to step (a) of the method for assessing a hematological disease described herein, and

[0089] (II) based on the result of step (I) stratifying said subjects.

[0090] The method for stratifying is essentially similar to the method for assessing described herein, however, it is performed on a cohort of subjects, and, thus, the result of the method preferably is allocation of the members of the cohort to one of at least two subgroups differing in their T cell reactivity. Thus, the method for stratifying may e.g. be used for allocating subjects to treatment groups, e.g. to receive immunotherapy or not, to pre-select subjects for scientific study purposes, to establish study cohort for retrospectively analyze mechanisms of action and / or resistance development in immunotherapy, identification of subjects carrying reactive T cells, e.g. for identification of reactive T cells clones, and the like.

[0091] The present invention further relates to a system comprising an evaluation device with a data processor, the evaluation device comprising instructions configured for performing the method according as specified herein.Deutsches Krebsforschungszentrum 27 DK17411PC Stiftung des öffentlichen Rechts et al.

[0092] The term “system”, as used herein, relates to a combination of means comprising the aforementioned units operatively linked to each other to allow obtaining the amount of a biomarker and evaluation thereof according to a method as specified herein, such that an assessment can be provided. Preferably, the assessing by the system is carried out according to a method as described herein above. Preferably, said assessing is carried out by the evaluation device by carrying out a comparison of the amounts of the biomarkers to at least one reference and / or by carrying out a calculation of a score for assessing based on the amount of the biomarker. Preferably, said comparison and / or said calculation is performed according a method as described elsewhere herein.

[0093] The evaluation device comprises at least one data processor, which may also be referred to as a "data processing unit", with an implemented algorithm for at least determining the amount of biomarker present in a sample, and, optionally, comparing said amount to a reference. Appropriate data processing units are known in the art. In general, a data processing unit comprises a processor capable of executing a plurality of instructions (such as a program of software). Said data processor may e.g. be comprised in a general purpose computer or a computing system, which may be portable or stationary. It should also be understood that multiple computers or computing systems may be used together, such as over a network or other methods of transferring data, for performing one or more steps of the methods disclosed herein.

[0094] The evaluation device typically further comprises or has access to a memory. A memory is a computer readable information storage medium and may comprise a single storage system or multiple storage systems, located either locally with the computing system or accessible to the computing system across a network, for example.

[0095] The evaluation device, preferably, further comprises a database as specified herein elsewhere. The system may also comprise or have access to an output device. Exemplary output devices include displays, printers, files, and telecommunication systems, such as fax systems, data servers, and the like. According to some embodiments, an evaluation device may perform one or more steps of a method disclosed herein, and thereafter provide an output, via an output device, relating to an assessment result, indication, ratio or other factor of the method. The system may also comprise or have access to an input device, such as a keyboard reader, a dataDeutsches Krebsforschungszentrum 28 DK17411PC Stiftung des öffentlichen Rechts et al.

[0096] connection to an analytic device, or any other input device deemed appropriate by the skilled person.

[0097] Preferably, the system further comprises, operably connected to the evaluation device, an analytic device configured for determining the biomarker or biomarkers in the sample. The analytic device, typically, comprises a means for biomarker determination (determination means) and, optionally, a means for separating the biomarker from other sample constituents (separation means), such as a chromatographic device. The separation means and the determination means are, preferably, functionally coupled to each other. Exemplary means for biomarker determination comprise mass spectrometry devices. The biomarker may, however, also be determined by contacting with a detection agent, preferably as specified herein above. In such case, the analytic device, typically, comprises at least one reaction zone having a detection agent for the biomarker. The device may comprise one or more further detection agent(s) for one or more further, optional biomarker(s). The detection agent may be comprised in immobilized form on a solid support or carrier which is to be contacted to the sample. The detection agent may, however, also be comprised e.g. in liquid form in the device. Moreover, the reaction zone shall preferably be connected to a detection means, which may also be referred to as a "detector". The connection shall be such that the detector can detect the result of a detection reaction, e.g. the binding of the biomarker to its detection agent(s), an enzymatic reaction, or an ion detectable in a mass spectrometry device. Suitable detectors depend on the techniques used for measuring the presence or amount of the biomarker. The determined amount can be subsequently transmitted to the evaluation device. The analytic device may, however, also comprise a sequencing means, preferably configured for single-cell RNA sequencing. Thus, the system may e.g. be a single-cell sequencing device, as such in principle known in the art and commercially available, configured for performing a method as described herein.

[0098] The present invention also relates to a kit for assessing hematological disease comprising detection agents configured for specifically determining at least five biomarkers selected from the list consisting of the biomarkers of indicated in Table 1, preferably comprised in a housing.

[0099] The term “kit” as used herein refers to a collection of the components indicated, typically provided in separate compound(s) or as a mixture of compounds. The means are, preferably, provided in a single container (i.e. a housing), preferably enabling common translocation, e.g.Deutsches Krebsforschungszentrum 29 DK17411PC Stiftung des öffentlichen Rechts et al.

[0100] transport, of the components. The container also typically comprises instructions for carrying out the method of the present invention. These instructions may be in the form of a manual or may be provided by a computer program code which is capable of carrying out or supports the determination of the biomarkers referred to in the methods of the present invention when implemented on a computer or a data processing system. The computer program code may be provided on a data storage medium. Moreover, the kit may, usually, comprise standards for reference amounts of biomarkers for calibration purposes. The kit may also comprise further components which are necessary for carrying one of the methods described herein, may assist in doing so, or may provide further functions; preferably, the further component is a solvent, a buffer, a diluent, a washing solution and / or one or more reagent(s) required for detection of a biomarker. Thus, the kit may further comprise at least one of a diluent, a calibration means, a reference solution, a control solution, a specifier, and an enhancer. Further, the kit may comprise the system of the invention either in parts or in its entirety. Also, the kit may comprise a database as specified herein elsewhere, preferably tangibly embedded on a storage means.

[0101] The present invention also relates to a database comprising amounts of at least five, preferably at least ten, more preferably at least 15, even more preferably at least 20, most preferably all, of the biomarkers indicated in Table 1, allocated to at least one assessment of a hematological disease.

[0102] The term “database”, as used herein, refers to a collection of data which may be physically and / or logically grouped together and which are, preferably, tangibly embedded on a storage means. Accordingly, the database preferably comprises an allocation of references to assessment results, in particular the amounts of biomarkers allocated to at least one assessment of a hematological disease. As the skilled person understands from the description herein above, "stored references for amounts of biomarkers" may also be one or more scores derived from said references, threshold values, reference ranges, one or more score(s), and the like. The database, preferably, comprises further data, such as upper and / or lower detection limits, references for further biomarkers, in particular those described herein above, data relevant for plausibility checks, and the like. Preferably, the database comprises data on one or more assay methods to use, lot-specific data, e.g. for calibrator samples, and the like. Preferably, the database may be implemented in a single data storage medium or in physically separated data storage media being operatively linked to each other. Preferably, the database comprises a data collection on a suitable storage medium, preferably tangible embedded thereon. Moreover, theDeutsches Krebsforschungszentrum 30 DK17411PC Stiftung des öffentlichen Rechts et al.

[0103] database, preferably, further comprises a database management system. The database management system is, preferably, a network-based, hierarchical or object-oriented database management system. Preferably, the database is structured as to allow a search algorithm to compare a test data set with the data sets, in particular the references, comprised by the data collection. Specifically, by using such an algorithm, the database can be searched for similar or identical data sets being indicative for a medical condition or effect as set forth above (e.g. a query search). Thus, preferably, if a data set fulfilling the comparison criteria as detailed elsewhere herein can be identified in the database, the test data set will be associated with the said medical condition or effect. Consequently, the information obtained from the database can be used, e.g., as a reference for the methods described elsewhere herein.

[0104] The present invention further relates to at least five, preferably at least ten, more preferably at least 15, even more preferably at least 20, most preferably all, of the biomarkers indicated in claim 1 or detection agents therefor for use in assessing disease; and to a use of at least five, preferably at least ten, more preferably at least 15, even more preferably at least 20, most preferably all, of the biomarkers indicated in claim 1 or detection agents therefor, for the manufacture of a diagnostic.

[0105] Also, the present invention relates to at least five, preferably at least ten, more preferably at least 15, even more preferably at least 20, most preferably all, of the biomarkers indicated in claim 1 or detection agents therefor, for use in assessing hematological disease; and to a use of at least five, preferably at least ten, more preferably at least 15, even more preferably at least 20, most preferably all, of the biomarkers indicated in claim 1 or detection agents therefor, for the manufacture of a diagnostic for assessing hematological disease.

[0106] The present invention also relates to a method for assessing and treating hematological disease in a subject suffering therefrom, said method comprising

[0107] (A) assessing said hematological disease in said subject using the method for assessing described herein, and

[0108] (B) treating said hematological disease in said subject based on the assessing in step (A).

[0109] A method for identifying a subject suffering from hematological disease as susceptible for treating with a pre-determined hematological disease therapy, said method comprisingDeutsches Krebsforschungszentrum 31 DK17411PC Stiftung des öffentlichen Rechts et al.

[0110] (AA) assessing said hematological disease in said subject using the method for assessing described herein; and

[0111] (BB) based on the assessing in step (AA), identifying the subject as susceptible for treating with said pre-determined hematological disease therapy, or not.

[0112] The term “identifying” a subject, as used herein, refers to making a subject known to have a pre-determined property, i.e. preferably to assigning a feature to the subject, i.e. the feature of being susceptible to treating with a pre-determined hematological disease therapy, or not. As will be understood by those skilled in the art, such an identification is usually not intended to be correct for 100% of the subjects to be investigated. The term, however, requires that the assignment, i.e. the identification, is correct for a statistically significant portion of subjects (e.g. in a cohort in a cohort study).

[0113] The term “susceptible to a therapy”, as used herein, means that a subject profits from a therapy as referred to in accordance with the present invention; thus, the subject preferably responds to said therapy, preferably by amelioration of symptoms of disease. A response of the subject, preferably, is a therapeutic response. A therapeutic response means that the subject shows amelioration, cure or other improvement of a hematological disease or symptoms associated with said hematological disease and / or that aggravation of the hematological disease and / or its symptoms is prevented.

[0114] The method for identifying comprises step (AA) assessing said hematological disease in said subject using the method as specified herein. In step (AA) of the method for identifying, the assessing preferably comprises assessing whether the subject suffers from a non-immune responsive or from an immune responsive form of a hematological disease, and / or whether the subject is at risk of deterioration of said hematological disease. As described herein above, said assessing may comprise one or more further diagnostic steps.

[0115] The method for identifying further comprises step (BB) based on the assessing in step (AA), identifying the subject as susceptible for treating with said pre-determined hematological disease therapy, preferably immunotherapy, or as not susceptible for treating with said predetermined hematological disease therapy. In view of the description herein, the skilled person understands that preferably a subject is identified to be susceptible to therapy if it is assessed (i.e. ruled-in) to suffer from an immune responsive form of a hematological disease and / or isDeutsches Krebsforschungszentrum 32 DK17411PC Stiftung des öffentlichen Rechts et al.

[0116] assessed not (i.e. ruled out) to suffer from an immune responsive form of a hematological disease; thus, the therapy the subject identified to be susceptible to therapy preferably is therapy of an immune responsive form of hematological disease as described herein above. Also preferably a subject is identified to be not susceptible to said therapy if it is assessed (i.e. ruledin) to suffer from a non-immune responsive form of a hematological disease and / or if it is assessed not (i.e. ruled out) to suffer from an immune responsive form of a hematological disease.

[0117] Moreover, the present invention also relates to a use of one or more detection agent(s) configured for specifically determining at least five, preferably at least ten, more preferably at least 15, even more preferably at least 20, most preferably all, of the biomarkers indicated in Table 1 for assessing hematological disease.

[0118] Summarizing the findings of the present invention, the following embodiments are particularly envisaged:

[0119] Embodiment 1: A method for assessing a hematological disease in a sample of a subject, said method comprising

[0120] (a) determining in said sample at least five, preferably at least six, more preferably at least seven, even more preferably at least eight, still more preferably at least nine, biomarkers selected from the list consisting of

[0121] (b) GNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, CCL5, HOPX, KLRD1, EFHD2, CD8A, CTSW, CST7, ITGB1, BHLHE40, LYAR, S100A4, GZMA, MXRA7, KLRK1, SH3BGRL3, ITGA4, FCRL6, TGFB1, CCL4, ZEB2, AOAH, AHNAK, S100A10, LGALS1, PRF1, ITGB2, CD52, TPST2, PRSS23, ANXA1, CYBA, C12orf75, LAIR2, MATK, S100A6, TNFAIP3, CLIC1, KLF6, C1orf21, SYNE2, HLA-DPB1, HLA-DPA1, DSTN, CD99, TAGLN2, PLEK, LINC02446, RPS26, RGCC, NFKBIA, FOS, PPP2R5C, CRIP1, AKAP13, ZFP36, and FLNA; and

[0122] (c) thereby assessing said hematological disease.

[0123] Embodiment 2: The method of embodiment 1, wherein said biomarkers comprise the biomarkers GNLY, ZNF683, GZMH, FGFBP2, and GZMB.

[0124] Embodiment 3: The method of embodiment 1 or 2, wherein step (a) comprises determining at least ten, preferably at least eleven, more preferably at least twelve, even more preferably at least 13, still more preferably at least 14, biomarkers.Deutsches Krebsforschungszentrum 33 DK17411PC Stiftung des öffentlichen Rechts et al.

[0125] Embodiment 4: The method of any one of embodiments 1 to 3, wherein said biomarkers comprise the biomarkers GNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, CCL5, HOPX, KLRD1, andEFHD2.

[0126] Embodiment 5: The method of any one of embodiments 1 to 4, wherein step (a) comprises determining at least 15, preferably at least 20, more preferably at least 30, even more preferably at least 40, still more preferably at least 50, most preferably all, biomarkers.

[0127] Embodiment 6: The method of any one of embodiments 1 to 5, wherein said biomarkers comprise the biomarkers GNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, CCL5, HOPX, KLRD1, EFHD2, CD8A, CTSW, CST7, ITGB1, and BHLHE40.

[0128] Embodiment 7: The method of any one of embodiments 1 to 6, wherein said biomarkers comprise the biomarkers GNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, CCL5, HOPX, KLRD1, EFHD2, CD8A, CTSW, CST7, ITGB1, BHLHE40, LYAR, S100A4, GZMA, MXRA7, and KLRK1.

[0129] Embodiment 8: The method of any one of embodiments 1 to 7, wherein said biomarkers comprise the biomarkers GNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, CCL5, HOPX, KLRD1, EFHD2, CD8A, CTSW, CST7, ITGB1, BHLHE40, LYAR, S100A4, GZMA, MXRA7, KLRK1, SH3BGRL3, ITGA4, FCRL6, TGFB1, CCL4, ZEB2, AOAH, AHNAK, S100A10, and LGALS1.

[0130] Embodiment 9: The method of any one of embodiments 1 to 8, wherein said biomarkers comprise the biomarkers GNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, CCL5, HOPX, KLRD1, EFHD2, CD8A, CTSW, CST7, ITGB1, BHLHE40, LYAR, S100A4, GZMA, MXRA7, KLRK1, SH3BGRL3, ITGA4, FCRL6, TGFB1, CCL4, ZEB2, AOAH, AHNAK, S100A10, LGALS1, PRF1, ITGB2, CD52, TPST2, PRSS23, ANXA1, CYBA, C12orf75, LAIR2, and MATK.

[0131] Embodiment 10: The method of any one of embodiments 1 to 9, wherein said biomarkers comprise the biomarkers GNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, CCL5, HOPX, KLRD1, EFHD2, CD8A, CTSW, CST7, ITGB1, BHLHE40, LYAR, S100A4, GZMA, MXRA7, KLRK1, SH3BGRL3, ITGA4, FCRL6, TGFB1, CCL4, ZEB2, AOAH, AHNAK, S100A10, LGALS1, PRF1, ITGB2, CD52, TPST2, PRSS23, ANXA1, CYBA, C12orf75, LAIR2, MATK, S100A6, TNFAIP3, CLIC1, KLF6, C1orf21, SYNE2, HLA-DPB1, HLA-DPA1, DSTN, and CD99.

[0132] Embodiment 11: The method of any one of embodiments 1 to 10, wherein said method comprises the further step of comparing the biomarkers determined in step (a) to a reference and assessing said infectious disease in step (b) based on said comparing.Deutsches Krebsforschungszentrum 34 DK17411PC Stiftung des öffentlichen Rechts et al.

[0133] Embodiment 12: The method of any one of embodiments 1 to 11, wherein said hematological disease is a hematological neoplasia.

[0134] Embodiment 13: The method of any one of embodiments 1 to 12, wherein said hematological disease is a non-tumor forming cancer.

[0135] Embodiment 14: The method of any one of embodiments 1 to 13, wherein said hematological disease is a myeloma, preferably a multiple myeloma or an acute myeloid leukemia (AML).

[0136] Embodiment 15: The method of any one of embodiments 1 to 14, wherein said assessing comprises identification a presence and / or quantification of T cells in a reactive status.

[0137] Embodiment 16: The method of any one of embodiments 1 to 15, wherein said assessing comprises determining a T cell immune status in a subject.

[0138] Embodiment 17: The method of any one of embodiments 1 to 16, wherein said assessing comprises predicting a therapy success.

[0139] Embodiment 18: The method of any one of embodiments 1 to 17, wherein said assessing comprises predicting a success of an immunotherapy.

[0140] Embodiment 19: The method of any one of embodiments 1 to 18, wherein said assessing comprises identifying a subject susceptible to immunotherapy.

[0141] Embodiment 20: The method of any one of embodiments 1 to 19, wherein said assessing comprises predicting immune mediated toxicity, preferably in said immunotherapy.

[0142] Embodiment 21: The method of any one of embodiments 1 to 20, wherein said assessing comprises immunotherapy monitoring.

[0143] Embodiment 22: The method of any one of embodiments 1 to 21, wherein said assessing comprising determining T cell fitness.

[0144] Embodiment 23: The method of any one of embodiments 1 to 22, wherein said immunotherapy comprises bispecific antibody (BiTE) therapy, checkpoint-inhibitor (ICB) therapy, CAR T cell therapy, and / or allogenic or autologous stem cell transplantation.

[0145] Embodiment 24: The method of any one of embodiments 1 to 23, wherein said therapy comprises immunotherapy.

[0146] Embodiment 25: The method of any one of embodiments 1 to 24, wherein step (a) comprises determining single-cell gene expression.

[0147] Embodiment 26: The method of any one of embodiments 1 to 25, wherein determining single-cell gene expression comprises determining said biomarkers and at least one housekeeping gene, and / or comprises determining a multitude of at least 100, preferably at least 200, more preferably at least 1000, non-biomarker genes.Deutsches Krebsforschungszentrum 35 DK17411PC Stiftung des öffentlichen Rechts et al.

[0148] Embodiment 27: The method of any one of embodiments 1 to 26, wherein step (a) comprises step (al) determining expression of said biomarkers in said sample relative to at least one reference on a single-cell level (cell score).

[0149] Embodiment 28: The method of any one of embodiments 1 to 27, wherein step (a) comprises step (a2) determining reactivity, proportion and / or absolute number of reactive T cells within at least one T cell clone of said sample (clone score), preferably based on a plurality of cell scores determined according to step (al).

[0150] Embodiment 29: The method of any one of embodiments 1 to 28, wherein step (a) comprises step (a3) determining a score indicative of clone number and / or clone reactivity in a subject (patient score), preferably based on a plurality of clone scores determined according to step (a2) and / or a plurality of cell scores determined according to step (al).

[0151] Embodiment 30: The method of any one of embodiments 1 to 29, wherein said patient score comprises at least one parameter selected from the list consisting of number of reactive clones, fraction of reactive clones of all clones analyzed, average clone score of reactive clones, size of reactive clones, and sum of clone scores of reactive clones.

[0152] Embodiment 31: The method of any one of embodiments 1 to 30, wherein said sample is a blood or blood-derived sample or a bone marrow derived sample.

[0153] Embodiment 32: A method for determining T cell reactivity in a sample comprising (i) step (a) of the method for assessing a hematological disease according to any one of embodiments 1 to 31; and

[0154] (ii) determining T cell reactivity based on the result of step (i).

[0155] Embodiment 33: The method of embodiment 32, wherein said method is an in vitro method.

[0156] Embodiment 34: The method of embodiment 32 or 33, wherein said sample is a sample of cells cultured in vitro.

[0157] Embodiment 35: A method for stratifying subjects according to their T cell reactivity, comprising

[0158] (I) determining in samples from said subjects at least five biomarkers according to step (a) of the method for assessing a hematological disease according to any one of embodiments 1 to 31, and

[0159] (II) based on the result of step (I) stratifying said subjects.

[0160] Embodiment 36: The method of embodiment 35, wherein said stratifying comprises identifying a subject as susceptible, or not, to immunotherapy.

[0161] Embodiment 37: The method of any one of embodiments 1 to 36, wherein said method isDeutsches Krebsforschungszentrum 36 DK17411PC Stiftung des öffentlichen Rechts et al.

[0162] computer-implemented.

[0163] Embodiment 38: The method of any one of embodiments 1 to 37, wherein said method is implemented on a system according to any one of embodiments 39 to 44.

[0164] Embodiment 39: A system comprising an evaluation device with a data processor, the evaluation device comprising instructions configured for performing a method according to any one of embodiments 1 to 38 and 57 to 59.

[0165] Embodiment 40: The system of embodiment 39, wherein said determining is obtaining amounts of said biomarkers, preferably from a database or a memory unit.

[0166] Embodiment 41: The system of embodiment 40, wherein said evaluation device further comprises instructions for carrying out a comparison of the amounts of the biomarkers to at least one reference.

[0167] Embodiment 42: The system of any one of embodiments 39 to 41, further comprising at least one of an output device and / or an input device.

[0168] Embodiment 43: The system of any one of embodiments 39 to 42 further comprising, operably connected to the processor, an analytic device configured for determining at least five, most preferably all, of said biomarkers.

[0169] Embodiment 44: The system of embodiment 43, wherein said analytic device comprises a detection agent for at least five, most preferably all, of said biomarkers.

[0170] Embodiment 45: A kit for assessing hematological disease comprising detection agents configured for specifically determining at least five biomarker selected from the list consisting of the biomarkers of indicated in embodiment 1, preferably comprised in a housing.

[0171] Embodiment 46: The kit of embodiment 45, further comprising a database according to embodiment 47.

[0172] Embodiment 47: A database comprising amounts of at least five, preferably at least ten, more preferably at least 15, even more preferably at least 20, most preferably all, of the biomarkers indicated in embodiment 1, allocated to at least one assessment of a hematological disease.

[0173] Embodiment 48: At least five, preferably at least ten, more preferably at least 15, even more preferably at least 20, most preferably all, of the biomarkers indicated in embodiment 1 or detection agents therefor for use in assessing disease.

[0174] Embodiment 49: Use of at least five, preferably at least ten, more preferably at least 15, even more preferably at least 20, most preferably all, of the biomarkers indicated in embodiment 1 or detection agents therefor, for the manufacture of a diagnostic.

[0175] Embodiment 50: At least five, preferably at least ten, more preferably at least 15, evenDeutsches Krebsforschungszentrum 37 DK17411PC Stiftung des öffentlichen Rechts et al.

[0176] more preferably at least 20, most preferably all, of the biomarkers indicated in embodiment 1 or detection agents therefor, for use in assessing hematological disease.

[0177] Embodiment 51: Use of at least five, preferably at least ten, more preferably at least 15, even more preferably at least 20, most preferably all, of the biomarkers indicated in embodiment 1 or detection agents therefor, for the manufacture of a diagnostic for assessing hematological disease.

[0178] Embodiment 52: A method for assessing and treating hematological disease in a subject suffering therefrom, said method comprising

[0179] (A) assessing said hematological disease in said subject using the method according to any one of embodiments 1 to 31 and 57 to 59, and

[0180] (B) treating said hematological disease in said subject based on the assessing in step (a). Embodiment 53: A method for identifying a subject suffering from hematological disease as susceptible for treating with a pre-determined hematological disease therapy, said method comprising

[0181] (A) assessing said hematological disease in said subject using the method according to any one of embodiments 1 to 31 and 57 to 59; and

[0182] (B) based on the assessing in step (A), identifying the subject as susceptible for treating with said pre-determined hematological disease therapy, or not.

[0183] Embodiment 54: The method of embodiment 53, wherein said hematological disease therapy comprises administration of a therapy as specified in embodiment 23 and / or 24.

[0184] Embodiment 55: Use of one or more detection agent(s) configured for specifically determining at least five, preferably at least ten, more preferably at least 15, even more preferably at least 20, most preferably all, of the biomarkers indicated in embodiment 1 for assessing hematological disease.

[0185] Embodiment 56: The subject matter of any of the preceding embodiments, wherein said assessing comprises prognosticating hematological disease, surveilling hematological disease therapy, predicting and / or diagnosing hematological disease or hematological disease relapse, assessing whether said subject is susceptible to a pre-determined hematological disease therapy, establishing a recommendation for further hematological disease therapy of said subject, diagnosing or aiding in diagnosing hematological disease.

[0186] Embodiment 57: The method of any one of embodiments 1 to 38, wherein step (a) comprises step (al) determining expression of said biomarkers in said sample relative to at least one reference on a single-cell level (cell score); comprises step (a2) determining reactivity, proportion and / or absolute number of reactive T cells within at least one T cell clone of saidDeutsches Krebsforschungszentrum 38 DK17411PC Stiftung des öffentlichen Rechts et al.

[0187] sample (clone score), based on a plurality of cell scores determined according to step (al), and comprises step (a3) determining a score indicative of clone number and / or clone reactivity in a subject (patient score), based on a plurality of clone scores determined according to step (a2) and / or a plurality of cell scores determined according to step (al).

[0188] Embodiment 58: The method of embodiment 57, wherein the biomarkers of embodiment 6 are determined.

[0189] Embodiment 59: The method of embodiment 57 or 58, wherein said patient score comprises at least one parameter selected from the list consisting of number of reactive clones, fraction of reactive clones of all clones analyzed, average clone score of reactive clones, size of reactive clones, and sum of clone scores of reactive clones.

[0190] All references cited in this specification are herewith incorporated by reference with respect to their entire disclosure content and the disclosure content specifically mentioned in this specification.

[0191] Figure Legends

[0192] Fig. 1: Generation of the TfiT signature and benchmarking as predictive tool for tumor-reactive T cells: (a) RNA expression of the TfiT signature genes in T cells of different functional specificities in a single-cell RNA dataset from n = 15 myeloma patients, defined by their respective T cell receptor, (b) ROC analysis of the predictive power for tumor-reactive T cells of the TfiT signature and published signatures (Caushi et al. (2021) and Lowery et al. (2022)) in a prospective cohort of n = 9 myeloma patients.

[0193] Fig. 2: TfiT predicts TCRs driving induction therapy response in newly diagnosed multiple myeloma (NDMM): (a) Graphical overview of the patient cohort and experimental workflow. Fifteen NDMM patients were profiled by single-cell RNA sequencing (scRNA-seq) and singlecell TCR sequencing (scTCR-seq) at baseline (pre-treatment), after cycle 5 of standard-of-care (SoC) therapy with daratumumab, bortezomib, thalidomide, and dexamethasone (Dara-VTd), and after autologous stem cell transplantation (ASCT). Patient-derived T cells were classified at baseline, and the clonal dynamics of each TCR were traced longitudinally, (b) TCR clonal dynamics over time in a representative NDMM patient following ASCT. Each area in the alluvial plot represents a single TCR clone identified by single-cell V(D)J sequencing (scVDJ-seq). The height of each bar at baseline or post-therapy reflects the proportional abundance ofDeutsches Krebsforschungszentrum 39 DK17411PC Stiftung des öffentlichen Rechts et al.

[0194] each clone within the total TCR repertoire at that timepoint. Clone colors indicate presence in the peripheral blood stem cell (PBSC) product. Anti-tumor reactivity was determined using the TfiT signature at the clone level at diagnosis (tumor-reactive = clone-aggregated signature score > 0.55; non-reactive = clone-aggregated signature score < 0.55). (c-e) Clonal dynamics in nine patients with paired scRNA-seq and scVDJ-seq data pre- and post-therapy. Significant clonotype dynamics were identified using a bootstrapping approach stratified by the number of cells per timepoint, followed by Benjamini-Hochberg correction for multiple testing. Reactivity (termed tumor) was determined for each clone using the TfiT signature on a per clone basis, (f) Box plot showing the average number of tumor-reactive TCRs detected in the bone marrow of NDMM patients at initial diagnosis, stratified by remission status after induction (immuno-)chemotherapy (VGPR, very good partial remission; CR, complete remission; sCR, stringent complete remission), (g, h) Bar charts showing the average number of tumor-reactive TCRs detected in the bone marrow at diagnosis (g) and the frequency of tumor-reactive bone marrow T cells (BMTCs) per TfiT signature (h), stratified by remission status after induction (immuno-)chemotherapy. Statistical significance between response groups was assessed using unpaired t-tests with Welch’s correction.

[0195] Fig. 3: TfiT predicts immunotherapy responses in relapsed / refractory multiple myeloma (RRMM) and acute myeloid leukemia (AML): (a) Graphical overview of the patient cohort and experimental workflow. Eighteen RRMM patients were profiled by single-cell RNA sequencing (scRNA-seq) and single-cell TCR sequencing (scTCR-seq) at baseline (pre-bispecific antibody, pre-bsAb), after cycle 1 of bispecific B cell maturation antigen x CD3 antibody (BCMA x CD3 bsAb) treatment, and after cycle 3 or at relapse. Patient-derived T cells were classified at baseline using TfiT, and the clonal dynamics of each TCR were tracked over time, (b-d) Longitudinal changes in the proportion of TCRs before and after bsAb treatment according to their predicted reactivity status (n = 16 patients with matched timepoints). Statistical significance was assessed using repeated-measures two-way ANOVA followed by Tukey’s test for multiple comparisons, (e) Expansion of complete response (CR)-associated TCRs following bispecific antibody treatment, stratified by TfiT-predicted T cell specificities. Statistical significance was determined by paired t-test. (f) Uniform manifold approximation and projection (UMAP) and alluvial plot of TCR clonotype dynamics in a representative clinical responder (patient MM-45) between baseline (pre-bsAb) and post-cycle 3 bsAb treatment, (g) Alluvial plot of TCR clonotype dynamics in a representative clinical nonresponder (patient MM-44) between baseline (pre-bsAb) and disease relapse, (h) TfiT signatureDeutsches Krebsforschungszentrum 40 DK17411PC Stiftung des öffentlichen Rechts et al.

[0196] expression at the single-cell RNA-seq level comparing clinical non-responders (NR) and responders (R). (i) Graphical overview of the AML patient cohort and workflow. Eight relapsed / refractory AML patients were profiled by scRNA-seq and scTCR-seq at baseline (pretreatment), at best response to azacitidine plus nivolumab immunochemotherapy, and at relapse. T cells were classified at baseline using TfiT, and the clonal dynamics of each TCR were monitored over time, (j) Alluvial plot of bone marrow lymphocyte and blast dynamics in a representative clinical responder (patient AML-07) across baseline (A, pre-treatment), best response (B, partial remission [PR]), and relapse (C). (k)Fold change in TfiT expression among T cell cells in patient AML-07 between timepoints A / B (anti-tumor T cell response) and B / C (relapse development). (1) Fold change in TfiT expression among T cells across all patients, stratified by clinical response (NR, non-responder; R, responder). Statistical significance between response groups was determined by unpaired t-test with Welch’s correction, (m) Correlation between the expansion of tumor-reactive T cells (classified by the TfiT signature) and blast reduction in the bone marrow. Log10values plotted; Spearman correlation used for analysis.

[0197] Fig. 4: TFiT predicts immunotherapy response in relapsed / refractory AML; (A) Experimental workflow for scRNA-seq and scTCR-seq profiling of 8 relapsed / refractory AML (RR AML) patients treated with azacitidine plus nivolumab within the phase II AARON trial (NCT02397720). Bone marrow samples collected pre-treatment, during treatment, and at best response or progression; (B) fold change in TFiT+BMT frequency between pre-treatment and best response, stratified by clinical response. Statistical comparison by unpaired t-test with Welch's correction; (C) Average TFiT score per patient in n = 6 AML patients post-allogeneic stem cell transplantation (allo-HSCT), split by remission status (complete response versus relapse post-allo-HSCT). Statistical significance assessed using a linear mixed-effects model with donor as a random effect; R: response, Rel: relapse, SD: stable disease, NR:non-response.

[0198] Abbreviations:

[0199] RRMM, relapsed / refractory multiple myeloma; AML, acute myeloid leukemia; scRNA-seq, single-cell RNA sequencing; scTCR-seq, single-cell TCR sequencing; bsAb, bispecific antibody; BCMA, B cell maturation antigen; TCR, T cell receptor; UMAP, uniform manifold approximation and projection; PEX, progenitor-exhausted; NR, non-responder; R, responder; PR, partial remission; NDMM, newly diagnosed multiple myeloma; SoC, standard of care; Dara-VTd, daratumumab, bortezomib, thalidomide, dexamethasone; ASCT, autologous stemDeutsches Krebsforschungszentrum 41 DK17411PC Stiftung des öffentlichen Rechts et al.

[0200] cell transplantation; TCR, T cell receptor; TRVa / p-seq, TCR a / p sequencing; scVDJ-seq, single-cell V(D)J sequencing; PBSC, peripheral blood stem cell; TfiT, tumor-focused immune TCR predictor; VGPR, very good partial remission; CR, complete response; sCR, stringent complete remission; BMTC, bone marrow T cell; MM, multiple myeloma.

[0201] The following Examples shall merely illustrate the invention. They shall not be construed, whatsoever, to limit the scope of the invention.

[0202] Example 1: Basis and preprocessing

[0203] 1.1 Single-cell RNA sequencing and data preprocessing

[0204] For scRNA / VDJ / CITE-seq, BMNC were counted, split in 8 aliquots per patient sample and separately stained with TotalSeq™ hashtag antibodies (BioLegend) and fluorescently labeled antibodies before pooling for flow cytometry. Viable, CD45+ CD3+ cells were isolated by fluorescence-activated cell sorting on a BD Aria Fusion™ device. Single-cell capture, reverse transcription, and library preparation were carried out on the Chromium platform (10x Genomics) with the Single Cell 5' reagent v2 kit (10x Genomics) according to the manufacturer’s protocol using 40,000 cells as input per channel. Each pool of cells was tested for library quality and library concentration was assessed. Each of the final libraries were paired-end sequenced (26 and 92 bp) on one Illumina NovaSeq 6000 S2 lane. Raw sequencing data containing single-cell RNA, VDJ and cell hashing information were processed using CellRanger (version 7.1) with default processing parameters and the ‘multi’ command. The GRCh38 reference genome (version 2020-A) and GRCh38 V(D)J reference (version 7.1.0) were used accordingly.

[0205] 1.2 Single-cell transcriptomic analyses

[0206] Quality control and normalization

[0207] The single-cell RNA sequencing data were demultiplexed, and cells were classified into three categories: Hashtag-oligo singlets, doublets, or unassigned, using the HTODemux command in Seurat v5.0.1 (Hao et al. (2024)) with default settings. For each patient sample, additional heterotypic doublets were identified using the scDblFinder package. We utilized both hashtag information and heterotypic doublet identifications to remove doublets from the datasets for all downstream analyses. Before proceeding further, we selected only those cells that exhibited a productive ab-TCR. All datasets underwent normalization using SCTransform (Hafemeister et al. (2019)) and were compared to a reference dataset of pre-annotated bone marrow single-cellDeutsches Krebsforschungszentrum 42 DK17411PC Stiftung des öffentlichen Rechts et al.

[0208] RNA-seq from patients newly diagnosed with myeloma. This comparison enabled us to eliminate all CD3- cells, which were artifacts of sorting impurities from our single-cell RNA-seq data. We employed SCTransform-based reference mapping, as implemented in the MapQuery function in Seurat, following the guidelines provided in the vignette (satijalab.org / seurat / articles / sctransform_v2_vignette.html). Cells that exhibited more than 200 detected RNA features, contained less than 10% mitochondrial RNA, and were identified as non-doublets and pure CD3+ T-cells were designated as ‘HighQuality’.

[0209] B ackprojection of antigen-specific TCRs to single-cell transcriptomes

[0210] Tumor reactive T cells

[0211] For mapping of tumor-reactive TCRs identified by forward microfluidics-based screening, CDR3 sequences from both TRA and TRB chains were back-projected onto the patient-specific single-cell RNA / TCR sequencing dataset. Clonotypes were annotated using CellRanger, providing corresponding CDR3 sequences for either TRB or both TRA and TRB. Pairwise alignment was employed to compare the nucleotide and amino acid sequence similarities between the extracted and annotated sequences. We evaluated the CDR3 amino acid sequences for similarities and overlaps across all patients in both cohorts. When a perfect alignment was found for either both TRA and TRB or just the TRB sequences of a single-cell TCR (scVDJ) clonotype with a known tumor-reactive TCR, that scVDJ clonotype was classified as tumor-reactive.

[0212] Virus reactive T cells

[0213] Mapping of virus-reactive TCRs found in public databases was performed by exact matching of the CDR3 beta amino acid sequences of TCRs with those in the VDJdb database (Shugay et al. (2018)). We specifically focused on TCRbeta chains annotated for " CMV," " EBV," " InfluenzaA," and " SARS-CoV-2." For each patient, only TCRs from these databases that were annotated with matching HLA haplotypes (haplotype group: e.g., HLA-A*02) were considered. In the mapping process to single-cell datasets, MHC class I-restricted TCRs were mapped exclusively to CD8 / NKT annotated single cells, and MHC class Il-restricted TCRs were mapped only to CD4 annotated single cells. TCRs identified as reactive to multiple viruses or both viruses and tumors were marked as ambiguous unless specified otherwise.Deutsches Krebsforschungszentrum 43 DK17411PC Stiftung des öffentlichen Rechts et al.

[0214] TfiT scoring algorithm

[0215] Following single-cell transcriptomic analysis and b ackprojection of antigen-specific TCRs, T cell reactivity was assessed using the TfiT algorithm. This multi-stage computational method is designed for paired single-cell RNA sequencing and TCR sequencing data and processes the expression of the defined TfiT signature through a hierarchical scoring system to quantify T cell reactivity at the cell, clone, and patient levels. A detailed description of the algorithm is as follows:

[0216] 1 TfiT Algorithm: Identification of Tumor-Reactive T Cells Algorithm 1: TfiT: Multistage Identification of Tumor - Reactive T Cells (Part 1 of 2) Input: S: Set of scRNA-seq datasets (one dataset per patient);

[0217] At: Associated expression matrix (genes x cells), G x C;

[0218] T: TCR sequencing data with cell-to-clone mapping;

[0219] Csig: Set of signature genes,sigC

[0220] X: Vector of weights Xgfor each signature gene g

[0221] 9 Threshold for cell reactivity;

[0222] a: Threshold for clone reactivity (consensus);

[0223] P: Patient identifiers and cell / clone to patient mapping;

[0224] Output: C'rL,aclivc: Set of cells classified as reactive;

[0225] 2reactive: Set of clones classified as reactive (consensus clones);

[0226] S atient Patient-specific reactivity scores;

[0227] 1 Procedure ComputeCellScores(JA, Qsi^, X)

[0228] 2 Let C be the set of all cells and the set of all genes. Let A = |Gaii |;

[0229] 3 Initialize a map CellScores ■ C E R;

[0230] 4 for each cell c G C do

[0231] 5 Extract expression vector E(. = Jvt.

[0232] 6 Compute ranks Rankle, g' ) for all genes g' based on Ec(descending expression); 7 Compute the TfiT-CellScore:;

[0233] 8Score,. log / / Log-rank term

[0234]

[0235]

[0236] weighted by expression

[0237] 9 CellScores <• C Scorec;

[0238] io

[0239]

[0240] Return CellScores;

[0241] u Procedure ClassifyReactiveCells(CellScores. O)

[0242]

[0243] Deutsches Krebsforschungszentrum DK17411PC Stiftung des öffentlichen Rechts et al.

[0244] Algorithm 1: Continuation: TfiT: Multistage Identification of Tumor-Reactive T Cells (Part 2 of 2)

[0245] i Procedure ComputeCloneScores(T, CellScores. Creactive)

[0246] 2 Identify the set of all clones 1C from T;

[0247] 3 Initialize a map CloneScores ■ K. E JR;

[0248] 4 for each clone n G K do

[0249] 5 Determine the set of cells CK— {c G C | Clone(c) — n} from T;

[0250] 6 Determine reactive cells in the clone CPactlve= CKA Crcactivc;

[0251] 7 if | CK| > 0 then

[0252] 8 Compute reactivity fraction fK=p. |1;

[0253] 9 Compute mean cell score SK= CellScores [c];

[0254]

[0255] 10 Compute TfiT-CloneScore:;

[0256] 11 Scoreft. C fK■ SK■ \ / |Q;eactive|; / / Combines fraction, mean score, and size of the reactive subset 12

[0257]

[0258] CloneScores [K] C ScoreK;

[0259] 13 else

[0260] 14 |_ CloneScores [K] C 0;

[0261] 15 Return CloneScores;

[0262] 16 Procedure IdentifyReactiveClones(CloneScores, a)

[0263]

[0264] 23 Procedure AggregatePatientReactivity( / CreacliveCloneScores^ P. T)

[0265] 24 Initialize a map SPaticnt: PatientIDs E R with zeros;

[0266] 25 for each reactive clone K, E JCreactivedo

[0267] 26 Determine the patient p to which clone K belongs (using P or T);

[0268] 27 ^Patient M C Spatient [ ] + CloneScores [K]; / / Example: sum of scores of reactive clones

[0269] 28 Return 5Patient

[0270] 29 Final Integration: The results (Creactive, ^reactive, > SPatient) provide a multistage picture of T cell reactivity from the single-cell level to the patient cohort level.Deutsches Krebsforschungszentrum 45 DK17411PC Stiftung des öffentlichen Rechts et al.

[0271] 2 Cell Scoring

[0272] The new method combines expression strength with relative rank position and also uses a weighted differentiation of top-expressed genes:

[0273] Let:

[0274] • (sigbe the set of signature genes.

[0275] • j a gene fromsig.

[0276] • E c, g,j ) the expression of gene grjin cell c.

[0277] • Rank r.

[0278]

[0279] the rank of gene gtin cell c (1 - highest expression, N = lowest expression, where N is the total number of genes).

[0280] • A, an optional weighting factor, e.g., based on the importance of the gene for tumor reactivity.

[0281] The cell score equation (TfiT-CellScore) is defined as:

[0282] TfiT-CellScore( log

[0283]

[0284]

[0285] • The equation links gene expression linearly with the logarithmized rank position. • The logarithm emphasizes highly expressed genes (low rank) more strongly.

[0286] • A, allows gene-specific prior knowledge to be incorporated, which is a clear advantage over unweighted methods.

[0287] 3 Clone Scoring

[0288] The clone scoring aggregates information from cell-level scores within a clone in a robust manner. It weights both the number of reactive cells in the clone and their mean cell scores: Let:

[0289] • CKbe the set of all cells within a clone K.

[0290] • TfiT-CellScore(c) the cell score of each cell c E CK.

[0291] • 0 the threshold above which cells are considered ’’reactive.”

[0292] Define:

[0293] Creac -CellScore(c) > 0}

[0294] TfiT-CellScore( CellScore(c)

[0295]

[0296] The clone score equation (TfiT-CloneScore) is:

[0297] TfiT-CloneScore(

[0298]

[0299] fiT-CellScore(K) ■ KlKfactlve

[0300] • The equation combines mean reactivity, proportion, and absolute number of reactive cells.

[0301] • The square root function ensures that clones with many reactive cells are weighted more heavily but do not dominate linearly.Deutsches Krebsforschungszentrum 46 DK17411PC Stiftung des öffentlichen Rechts et al.

[0302] Example 2: Results

[0303] Example 2.1: Figure la

[0304] Differential Gene Expression (DGE) and establishment of gene signatures

[0305] DGE was carried out using presto v. 1.0.0 (github.com / immunogenomics / presto) wilcoxauc(, assay= “data”), TCR variable genes were filtered from DGE. For signature generation of Myeloma-reactive T cells the dataset was split into establishment (n=6 patients) and validation cohort (n=9). TfiT signature was generated based on DGE of the establishment cohort by downsampling the each reactivity group to max. 2000 cells, further filtering the top markers (p_val_adj < 0.01, logFC > 0.5) of Myeloma-reactive cells in comparison to respective Virus-Epitope reactive (CMV, EBV, InfluenzaA, Sars_CoV_2, ambiguous) and Bystander T cells.

[0306] 8 different iterations of the signature were tested by slicing top features ordered by DGE-auc value. Respective genes are shown in Table 2. Final signature (TfiT) included the top 15 genes ordered by auc ((p_val_adj < 0.01, logFC > 0.5). RNA expression of the TfiT signature genes in T cells of different functional specificities in a single-cell RNA dataset from n = 15 myeloma patients, defined by their respective T cell receptor is shown in Figure la.

[0307] Figure la shows the differential expression of the 15 genes included in TfiT across the defined functional specificities per TCR in the establishment cohort (n=6 patients).

[0308] Example 2.2: Figure lb

[0309] Benchmarking of TfiT-signature for tumor-reactivity prediction

[0310] Predictional value of the here established TfiT-signature and further literature derived signatures (Caushi, J. X. et al. (2021), Oliveira, G. et al. (2021), Lowery, F. J. et al. (2022)) were tested within the validation cohort (n=9 patients) by applying the described algorithm on a per-cell basis.

[0311] AUROC curves and AUC values were generated using the pROC v.1.18.5 package (Robin et al. (2011)), here tumor-reactive cells in the establishment cohort and validation cohort were termed 1 and all non-tumor-reactive cells 0 (closed world assumption) and used as the responseargument, the TfiT-CellScore score (enrichment score) was then used as predictor for the ROC analyses using the roc() function. AUROC curves were plotted by the ggroc() function. The coords() function was used to determine the TfiT-score (enrichment score) threshold of 0.48 exhibiting sensitivity and specificity > 0.8 in the validation cohort.Deutsches Krebsforschungszentrum 47 DK17411PC Stiftung des öffentlichen Rechts et al.

[0312] Figure lb shows ROC analysis of the predictive power for tumor-reactive T cells of the TfiT signature and selected published signatures (Caushi et al. (2021) and Lowery et al. (2022)) in a prospective cohort of n = 9 myeloma patients.

[0313] Example 2.3: Figure 2 a-e

[0314] scRNA / VDJ-seq analysis of PBSC products

[0315] Longitudinal assessment of the bone marrow of multiple myeloma at baseline, after stem cell transplantation and after one year of maintenance was done for (N=5) patients using scRNA and scVDJ sequencing. Additionally, the PBSC product of those five patients was analyzed by scRNA and scVDJ sequencing. After filtering all cells without a productive TCR, cells from 4 paired timepoints were used for downstream analysis. Datasets were mapped to the same reference of pre-annotated bone marrow T cell single-cell RNA-seq from newly diagnosed myeloma patients as above. Using paired TRA and TRB sequences, clonotypes were identified as shared or distinct across timepoints. The TfiT-algorithm was applied on a per-clone basis to classify tumor-reactive TCRs as opposed to orphan TCRs.

[0316] In Figure 2 b-e it can be demonstrated that TfiT-positive clonotypes expand significantly post-ASCT as compared to orphan TCRs (TfiT-negative) indicating that these cells drive anti-tumor response and delineating TfiT-expression as a longitudinal biomarker of immunotherapy response.

[0317] Example 2.4: Figure 2 f-h

[0318] Analysis of association between response to newly diagnosed multiple myeloma first-line therapy and TfiT-expression

[0319] Patients received standard induction therapy consisting of daratumumab, bortezomib, lenalidomide, and dexamethasone. The TfiT per cell algorithm was applied to the available cohort of n=15 patients. T cells were classified as TfiT-positive if the expression level of the TfiT signature exceeded the threshold of 0.48. The proportion of TfiT-positive T cells was calculated for each patient. Patients were then stratified into two groups based on their clinical response to therapy: complete response (CR; n = 11) and non-complete response (< CR; n = 8). Statistical comparison of the proportion of TfiT-positive T cells between CR and < CR groups was performed using an unpaired two-tailed Ltest with Welch’s correction to account for unequal variances.Deutsches Krebsforschungszentrum 48 DK17411PC Stiftung des öffentlichen Rechts et al.

[0320] Figures 2f-h demonstrates the significant association between clinical response to SoC NDMM therapy with Dara-VTd and number of experimentally identified tumor-reactive TCRs (2f-g) as well as the number of TfiT-positive cells prior to therapy administration, further underlining the predictive power of TfiT as a biomarker of tumor-reactivity as well as therapy response.

[0321] Example 2.5: Figure 3 a-i

[0322] Analysis of longitudinal relapsed refractory multiple myeloma bone marrow samples with bispecific antibody (bsAb) exposure

[0323] bsAb datasets (RRMM patients treated with a CD3-BCMA bispecific antibody) were mapped to the same reference of pre-annotated bone marrow T cell single-cell RNA-seq from newly diagnosed myeloma patients as above. TCR info was filtered and calculated as described above and only cells with productive TCR were analyzed. Virus reactivity was also determined based on exact CDR3 aa beta match with VDJdb (Shugay et al. (2018) as described above, without HLA-filtering. Overlapping TCRs were identified per patient using the full clonotype CDR3 amino acid sequence. Overlapping clonotypes with a ratio > 0.4 of cells above threshold across timepoints were termed reactive for the alluvial analysis. Plots of overlapping TCRs were generated using the ggalluvial (v.0.12.5) package.

[0324] The TfiT per cell algorithm was applied to the available cohort of n=18 patients. T cells were classified as TfiT-positive if the expression level of the TfiT signature exceeded the threshold of 0.48. The proportion of TfiT-positive cells per sample was calculated to test for statistical association to response categories. Statistical analysis was carried out by unpaired t-test with Welch ’s correction.

[0325] Figure 3b-g shows that also within the context of CD3-BCMA bispecific T cell engager (BCE) therapy TfiT-positive T cells significantly expand over the course of BCE exposure, compared to virus-reactive or bystander T cells, which is associated with therapy response (3f-i). Also within the context of BCE, TfiT expression and the number of TfiT positive T cells serves as a predictive as well as longitudinal biomarker for therapy response.

[0326] Example 2.6: Figure 3 (j-m)

[0327] Analysis of longitudinal relapsed or refractory acute myeloid leukemia bone marrow samples treated with azacitidine and nivolumab (Abbas et al. (2021)Deutsches Krebsforschungszentrum 49 DK17411PC Stiftung des öffentlichen Rechts et al.

[0328] AML datasets were mapped to the same reference of pre-annotated bone marrow T cell singlecell RNA-seq from newly diagnosed myeloma patients as above to annotate T cell subtypes. Only cells with annotated TCR were analyzed. The TfiT per cell algorithm was applied to the available cohort of n=8 AML patients. T cells were classified as TfiT-positive if the expression level of the TfiT signature exceeded the threshold of 0.48.

[0329] Correlative analyses between AML burden dynamic and TfiT dynamic were carried out for timepoints A (pre therapy) and B (post initial exposure (see Abbas et al. (2021, Figla)). AML burden data was extracted from Abbas et al. (2021). For each patient sample at each timepoint the average TfiT-expression of cells was used to calculate the fold change between timepoints B / A per patient. For AML burden, determined as percentage of blasts by flowcytometry, a foldchange B / A was calculated. Correlative analyses between AML burden dynamic and TfiT dynamic were done using the loglO-transformed FC. Linear regression was calculated using the R stats package using lm().

[0330] Figure 3j-m display the dynamic association of TfiT expression with anti -tumour activity as well as clinical response to immune checkpoint blockade in AML as a further hematological entity. In responding patients, the number of TfiT-positive T cells significantly expanded over the course of therapy, while non-responding patients displayed no signs of expansion of tumour-reactive T cells. Moreover, TfiT-expression dynamics were significantly inversely correlated on patient level with AML tumor burden (Figure 3m), further highlighting the biomarker potential of TfiT as a biomarker of T cell anti-tumor activity.

[0331] Example 2.7 Figure 4

[0332] Tumor-reactive T cells associate with responses to immunotherapy in AML

[0333] To test whether tumor-reactive T cells underlie responses to ICB, we re-analyzed paired scRNA-seq and scTCR-seq data from the phase II AARON trial (NCT02397720) of azacitidine plus nivolumab in relap sed / refractory (r / r) AML. This cohort comprised 22 longitudinal bone marrow samples from 8 patients, including 3 clinical responders, 3 non-responders, and 2 with stable disease (Figure 4A).

[0334] We applied TFiT to this dataset to determine whether pre-existing tumor-reactive T cells associate with clinical anti-leukemia response. TFiT-positive cells were detectable at baselineDeutsches Krebsforschungszentrum 50 DK17411PC Stiftung des öffentlichen Rechts et al.

[0335] and showed selective expansion in clinical responders following therapy. In contrast, nonresponders exhibited minimal or no expansion of tumor-reactive T cells, while patients with stable disease showed intermediate dynamics. Across the cohort, the magnitude of tumor-reactive T cell expansion - as inferred by TFiT - correlated with both flow cytometric blast reduction and overall clinical response (R2= 0.68, p = 0.0117), providing further support for the predictive relevance of BMTs with features of tumor reactivity.

[0336] In a complementary analysis of 6 AML patients post-allogeneic stem cell transplantation (allo-HSCT), a low average TFiT score was associated with early relapse after transplantation (Figure 4C).

[0337] These findings establish tumor-reactive BMTs as a mechanistic correlate of response to immunotherapy in AML and MM and validate the TFiT signature as a broadly applicable tool for their detection. Importantly, the specificity of TFiT for immunotherapy-mediated responses - supports its biological validity as a marker of T cell-mediated tumor control. Our approach provides tools for tracking endogenous antitumor immunity across disease states and therapeutic modalities, and offers a proof of concept for using the transcriptional features of functionally relevant T cell populations to guide patient stratification and immunotherapy development in bone marrow malignancies.

[0338] References

[0339] Danilova, L. et al. The Mutation- Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. Cancer Immunol Res 6, 888-899 (2018).

[0340] Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat. Biotechnol. 42, 293-304 (2024).

[0341] Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 20, 296 (2019).

[0342] Shugay, M. et al. VDJdb: a curated database of T-cell receptor sequences with known antigen specificity. Nucleic Acids Res 46, D419-D427 (2018).

[0343] Caushi, J. X. et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1 -treated lung cancers. Nature 596, 126-132 (2021).Deutsches Krebsforschungszentrum 51 DK17411PC Stiftung des öffentlichen Rechts et al.

[0344] Oliveira, G. et al. Phenotype, specificity and avidity of antitumour CD8(+) T cells in melanoma. Nature 596, 119–125 (2021).

[0345] Lowery, F. J. et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 375, 877–884 (2022).

[0346] Robin, X. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12, 77 (2011).

[0347] Friedrich, M. J. et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell (2023) 41:711.

[0348] Abbas, H. A. et al. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun 12, 6071 (2021).

[0349] Wang et al., Signal Transduct Target Ther (2022) 7:331

[0350] Catalano et al., Crit Rev Oncol Hematol (2023) 192:104135

[0351] Ligero et al., Trends Cancer (2025) 11 (3):232Deutsches Krebsforschungszentrum 52 DK17411PC Stiftung des öffentlichen Rechts et al.

[0352] Table 1: Biomarkers of the invention and their characteristics; Genbank Acc Nos for mRNA sequences and protein sequences are exemplary, the skilled person is aware that other sequences, e.g. other alleles, splice variants, and the like, may be used.

[0353]

[0354] Deutsches Krebsforschungszentrum 53 DK17411PC

[0355] Stiftung des öffentlichen Rechts et al.

[0356]

[0357] Table 2: Marker combinations and AUC values; NA: not applicable.

[0358]

[0359]

[0360] Deutsches Krebsforschungszentrum 56 DK17411PC

[0361] Stiftung des öffentlichen Rechts et al.

[0362]

Claims

Deutsches Krebsforschungszentrum 57 DK17411PC Stiftung des öffentlichen Rechts et al.Claims1. A method for assessing a hematological disease in a sample of a subject, said method comprising(a) determining in said sample at least five biomarkers selected from the list consisting ofGNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, CCL5, HOPX, KLRD1, EFHD2, CD8A, CTSW, CST7, ITGB1, BHLHE40, LYAR, S100A4, GZMA, MXRA7, KLRK1, SH3BGRL3, ITGA4, FCRL6, TGFB1, CCL4, ZEB2, AOAH, AHNAK, S100A10, LGALS1, PRF1, ITGB2, CD52, TPST2, PRSS23, ANXA1, CYBA, C12orf75, LAIR2, MATK, S100A6, TNFAIP3, CLIC1, KLF6, C1orf21, SYNE2, HLA-DPB1, HLA- DPA1, DSTN, CD99, TAGLN2, PLEK, LINC02446, RPS26, RGCC, NFKBIA, FOS, PPP2R5C, CRIP1, AKAP13, ZFP36, and FLNA; and(B) thereby assessing said hematological disease.

2. The method of claim 1, wherein said biomarkers comprise the biomarkers GNLY, ZNF683, GZMH, FGFBP2, and GZMB.

3. The method of claim 1 or 2, wherein step (a) comprises determining at least 15 biomarkers.

4. The method of any one of claims 1 to 3, wherein said biomarkers comprise the biomarkers GNLY, ZNF683, GZMH, FGFBP2, GZMB, NKG7, CCL5, HOPX, KLRD1, EFHD2, CD8A, CTSW, CST7, ITGB1, and BHLHE40.

5. The method of any one of claims 1 to 4, wherein said method comprises the further step of comparing the biomarkers determined in step (a) to a reference and assessing said infectious disease in step (b) based on said comparing.

6. The method of any one of claims 1 to 5, wherein step (a) comprises step (al) determining expression of said biomarkers in said sample relative to at least one reference on a single-cell level (cell score); comprises step (a2) determining reactivity, proportion and / or absolute number of reactive T cells within at least one T cell clone of said sample (clone score), based on a plurality of cell scores determined according toDeutsches Krebsforschungszentrum 58 DK17411PC Stiftung des öffentlichen Rechts et al.step (al), and comprises step (a3) determining a score indicative of clone number and / or clone reactivity in a subject (patient score), based on a plurality of clone scores determined according to step (a2) and / or a plurality of cell scores determined according to step (al).

7. The method of claim 6, wherein the biomarkers of claim 4 are determined.

8. The method of claim 6 or 7, wherein said patient score comprises at least one parameter selected from the list consisting of number of reactive clones, fraction of reactive clones of all clones analyzed, average clone score of reactive clones, size of reactive clones, and sum of clone scores of reactive clones.

9. The method of any one of claims 1 to 8, wherein said hematological disease is a hematological neoplasia, preferably a multiple myeloma or an acute myeloid leukemia (AML).

10. The method of any one of claims 1 to 9, wherein said assessing comprises determining a T cell immune status in a subject.

11. The method of any one of claims 1 to 10, wherein said assessing comprises identifying a subject susceptible to immunotherapy and / or comprises immunotherapy monitoring, preferably wherein said immunotherapy comprises bispecific antibody (BiTE) therapy, checkpoint-inhibitor (ICB) therapy, CAR T cell therapy, and / or allogenic or autologous stem cell transplantation.

12. The method of any one of claims 1 to 11, wherein said sample is a blood or blood- derived sample or a bone marrow derived sample.

13. An in vitro method for determining T cell reactivity in a sample comprising(i) step (a) of the method for assessing a hematological disease according to any one of claims 1 to 12; and(ii) determining T cell reactivity based on the result of step (i).

14. The method of any one of claims 1 to 13, wherein said method is computer-Deutsches Krebsforschungszentrum 59 DK17411PC Stiftung des öffentlichen Rechts et al.implemented, preferably on a system according to claim 15 or 16.

15. A system comprising an evaluation device with a data processor, the evaluation device comprising instructions configured for performing a method according to any one of claims 1 to 13.

16. The system of claim 15, further comprising, operably connected to the processor, an analytic device configured for determining at least five of said biomarkers.

17. A kit for assessing hematological disease comprising detection agents configured for specifically determining at least five biomarker selected from the list consisting of the biomarkers of indicated in claim 1 and a database according to claim 18.

18. A database tangibly embedded on a storage means comprising amounts of at least five biomarkers indicated in claim 1, allocated to at least one assessment of a hematological disease.